1 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
2 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
3 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
4 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
5 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
6 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
7 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
8 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
9 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 💬 |
10 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
11 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
12 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
13 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
14 | 0,5 mg seasonal influenza vaccine i.m. | - | - | - | - | 1件: 51 51 💬 |
15 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 💬 |
16 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 💬 |
17 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 💬 |
18 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 💬 |
19 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 💬 |
20 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
21 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
22 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
23 | 0.7mL prefilled syringes | - | - | - | - | 1件: 107 107 💬 |
24 | 0.9% w/v isotonic sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 50 50 💬 |
25 | 0.9% w/v sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
26 | 009-0 | - | - | - | - | 1件: 6 6 💬 |
27 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 💬 |
28 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 💬 |
29 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 💬 |
30 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 💬 |
31 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
32 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
33 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
34 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
35 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
36 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 💬 |
37 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
38 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
39 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 💬 |
40 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 💬 |
41 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
42 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
43 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
44 | 100 mg ELX /50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
45 | 100 mg ELX/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
46 | 100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
47 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
48 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
49 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
50 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
51 | 100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
52 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
53 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
54 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 💬 |
55 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
56 | 10000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
57 | 100g ELX / 50mg TEZ / 75mg IVA | - | - | - | - | 1件: 299 299 💬 |
58 | 100mg ELX/50mg TEZ /75mg IVA | - | - | - | - | 1件: 299 299 💬 |
59 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
60 | 13 valent conjugated pneumococcal vaccine | - | - | - | - | 1件: 265 265 💬 |
61 | 13-valent pneumococcal conjugate vaccine | - | - | - | - | 2件: 46 46, 53 💬 |
62 | 13-valent pneumococcal conjugate vaccine (13-PCV) | - | - | - | - | 1件: 13 13 💬 |
63 | 13-valent pneumococcal conjugated vaccine (PCV13) | - | - | - | - | 1件: 96 96 💬 |
64 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 💬 |
65 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
66 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
67 | 15-0 H20 | - | - | - | - | 2件: 6 6, 19 💬 |
68 | 18-F]DPA-714 | - | - | - | - | 1件: 127 127 💬 |
69 | 18F-DPA-714 and 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 1件: 13 13 💬 |
70 | 18F]DPA-714 | - | - | - | - | 2件: 13 13, 127 💬 |
71 | 19 nor vitamin d | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
72 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 💬 |
73 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
74 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
75 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
76 | 2011-2012 seasonal flu vaccine Intramuscular | - | - | - | - | 2件: 3 3, 113 💬 |
77 | 2011-2012 seasonal flu vaccine Subcutaneous | - | - | - | - | 2件: 3 3, 113 💬 |
78 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 💬 |
79 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
80 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
81 | 23-valent pneumococcal polysaccharide vaccine | - | - | - | - | 3件: 13 13, 46, 53 💬 |
82 | 23-valent pneumococcal polysaccharide vaccine (23-PPV) | - | - | - | - | 1件: 13 13 💬 |
83 | 23-valent polysaccharide pneumococcal vaccine | - | - | - | - | 1件: 96 96 💬 |
84 | 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM) | - | - | - | - | 2件: 96 96, 97 💬 |
85 | 25OH-Vitamin D | 2件: Cholecalciferol Cholecalciferol, Vitamin D | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 💬 |
86 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 💬 |
87 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
88 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
89 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
90 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
91 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
92 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
93 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
94 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
95 | 4D-710 | - | - | - | - | 1件: 299 299 💬 |
96 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 3件: Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 💬 |
97 | 5,6,7,8-tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
98 | 5-Hydroxytryptophan / Vitamin B6 | 1件: Pyridoxine Pyridoxine | 1件: Pyridoxine
Pyridoxine
💬 | - | - | 1件: 206 206 💬 |
99 | 5-methyltetrahydrofolate and vitamin B12 | 1件: Cyanocobalamin Cyanocobalamin | 4件: Cyanocobalamin
Cyanocobalamin
,
Cyanocobalamin Co 57
,
Cyanocobalamin Co 58
,
Cyanocobalamin Co 60
💬 | - | - | 1件: 299 299 💬 |
100 | 500 0500 0 | - | - | - | - | 1件: 19 19 💬 |
101 | 5000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
102 | 52069.00.01 | - | - | - | - | 1件: 13 13 💬 |
103 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 💬 |
104 | 552-02 | - | - | - | - | 2件: 53 53, 299 💬 |
105 | 56/104/75-C | - | - | - | - | 1件: 50 50 💬 |
106 | 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747 | - | - | - | - | 1件: 93 93 💬 |
107 | 6036937.00.01 | - | - | - | - | 1件: 6 6 💬 |
108 | 68GaNOTA-Anti-MMR-VHH2 | - | - | - | - | 1件: 84 84 💬 |
109 | 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
110 | 6a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
111 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
112 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
113 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
114 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
115 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
116 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
117 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
118 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
119 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
120 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
121 | 7-valent Pneumococcal Conjugate vaccine | - | - | - | - | 1件: 46 46 💬 |
122 | 70930.00.00 | - | - | - | - | 1件: 46 46 💬 |
123 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
124 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
125 | 98-92-0 | - | - | - | - | 1件: 107 107 💬 |
126 | 99mTc-rhAnnexin V-128 | - | - | - | - | 2件: 46 46, 271 💬 |
127 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
128 | [18F]DPA-714 PET | - | - | - | - | 1件: 2 2 💬 |
129 | [18F]DPA-714 PET scan | - | - | - | - | 1件: 6 6 💬 |
130 | [18F]P17-059 | - | - | - | - | 1件: 6 6 💬 |
131 | [18F]T807 ([18F]MNI-777) | - | - | - | - | 2件: 5 5, 6 💬 |
132 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 💬 |
133 | A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs | - | - | - | - | 1件: 46 46 💬 |
134 | A-1293543.74 | - | - | - | - | 1件: 96 96 💬 |
135 | A4250-015 | - | - | - | - | 1件: 297 297 💬 |
136 | AAV1-gamma-sarcoglycan vector injection | - | - | - | - | 1件: 113 113 💬 |
137 | AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
138 | AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
139 | Abatacept + Vaccines | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
140 | ABBV-006 | - | - | - | - | 1件: 97 97 💬 |
141 | ABBV-066 | - | - | - | - | 2件: 96 96, 97 💬 |
142 | ABBV-0805 | - | - | - | - | 1件: 6 6 💬 |
143 | ABBV-105, A-1519938.0 | - | - | - | - | 1件: 46 46 💬 |
144 | ABBV-CLS-7262 | - | - | - | - | 1件: 2 2 💬 |
145 | ABP 710 | - | - | - | - | 1件: 46 46 💬 |
146 | ABP 710 - Biosimilar to infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
147 | ABP 798 | - | - | - | - | 1件: 46 46 💬 |
148 | ABP 798 - Biosimilar to rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
149 | ABP 798 Biosimilar to Rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
150 | ABY-035 | - | - | - | - | 1件: 271 271 💬 |
151 | Access program - sildenafil citrate, Viagra, Revatio | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
152 | ACE-011 | - | - | - | - | 1件: 86 86 💬 |
153 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 💬 |
154 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 💬 |
155 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 💬 |
156 | ACE-031 (Extension of cohort 1 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
157 | ACE-031 (Extension of cohort 2 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
158 | ACE-031 (Extension of cohort 3 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
159 | ACE-031 0.5 mg/kg q4wk | - | - | - | - | 1件: 113 113 💬 |
160 | ACE-031 1.0 mg/kg q2wk | - | - | - | - | 1件: 113 113 💬 |
161 | ACE-083 | - | - | - | - | 2件: 10 10, 113 💬 |
162 | ACER-002 (celiprolol) 200 mg BID | 1件: Celiprolol Celiprolol | 1件: Celiprolol
Celiprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 💬 |
163 | Acetylsalicylic acid at 1st visit, | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
164 | ACH-0144471 | - | - | - | - | 2件: 62 62, 222 💬 |
165 | ACH-0144471 compresse | - | - | - | - | 1件: 222 222 💬 |
166 | ACH-0145228 | - | - | - | - | 1件: 62 62 💬 |
167 | ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable | - | - | - | - | 1件: 299 299 💬 |
168 | Acoziborole (SCYX-7158) | 1件: Acoziborole Acoziborole | - | - | - | 1件: 65 65 💬 |
169 | ACP-001 | - | - | - | - | 1件: 78 78 💬 |
170 | ACP-001 (TransCon hGH) | - | - | - | - | 1件: 78 78 💬 |
171 | ACP-011 | - | - | - | - | 1件: 78 78 💬 |
172 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
173 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
174 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
175 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
176 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
177 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
178 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
179 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
180 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 61 61, 62 💬 |
181 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 62 62, 66 💬 |
182 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
183 | Active Treatment Group 7% Hypertonic Saline | - | - | - | - | 1件: 299 299 💬 |
184 | Actrapid 100 IU/ml, Solution for injection in a vial | - | - | - | - | 1件: 299 299 💬 |
185 | ACZ885, 150mg/1.0ml | - | - | - | - | 2件: 266 266, 267 💬 |
186 | Ad26.COV2-S.02 | - | - | - | - | 1件: 299 299 💬 |
187 | Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
188 | Adderall XR | - | - | - | - | 1件: 13 13 💬 |
189 | Adderall XR 10 mg | - | - | - | - | 1件: 13 13 💬 |
190 | Adderall XR 5mg | - | - | - | - | 1件: 13 13 💬 |
191 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
192 | Adempas 0.125 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
193 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
194 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
195 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
196 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
197 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
198 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
199 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
200 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
201 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
202 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
203 | ADENO-ASSOCIATED VIRAL (AAV) SEROTYPE 8 (AAV2/8) VECTOR WITH LIVER-SPECIFIC THYROXINE-BINDING GLOBULIN (TBG) PROMOTER, DRIVING THE EXPRESSION OF THE HUMAN ARSB GENE | 1件: Levothyroxine Levothyroxine | 1件: Levothyroxine
Levothyroxine
💬 | 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 19 19 💬 |
204 | Adeno-associated viral vector serotype 3B encoding shortened human ATP7B | - | - | - | - | 1件: 171 171 💬 |
205 | Adeno-associated viral vector serotype 8 containing the human MD1 gene | - | - | - | - | 1件: 113 113 💬 |
206 | Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | - | - | - | - | 1件: 113 113 💬 |
207 | Adeno-associated viral vector serotype 9 containing the human N-acetyl-alpha-glucosaminidase gene | - | - | - | - | 1件: 19 19 💬 |
208 | Adeno-associated viral vector serotype 9 encoding human ATP7B | - | - | - | - | 1件: 171 171 💬 |
209 | ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 CONTAINING THE HUMAN CHOLESTEROL 24-HYDROXYLASE GENE | 1件: Cholesterol Cholesterol | 1件: Cholesterol
Cholesterol
💬 | - | - | 1件: 8 8 💬 |
210 | Adeno-associated virus (AAV) serotype rh.10 expressing human betagalactosidase (AAVrh.10-CAG-betagal) | - | - | - | - | 1件: 19 19 💬 |
211 | Adeno-associated virus (AAV) serotype rh.10 expressing human betagalactosidase (AAVrh.10-CAG-ßgal) | - | - | - | - | 1件: 19 19 💬 |
212 | Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA | 1件: Agalsidase alfa Agalsidase alfa | 1件: Agalsidase alfa
Agalsidase alfa
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
213 | Adeno-associated virus serotype 2/6 encoding Human Iduronate 2-sulfatase (hIDS) gene donor vector, SB-A6P-HNT Donor Vector | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
214 | Adeno-associated virus serotype 2/6 encoding human iduronidase (hIDUA) gene donor vector, SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
215 | Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector | - | - | - | - | 1件: 19 19 💬 |
216 | Adeno-associated virus serotype 2/6 encoding Right side-zinc finger nuclease (ZFN2), SB-A6P-ZRIGHT Vector | - | - | - | - | 1件: 19 19 💬 |
217 | ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE | - | - | - | - | 1件: 8 8 💬 |
218 | Adeno-associated virus serotype 9 carrying the human fukutin-related protein and target sequence of the miR-208a | - | - | - | - | 1件: 113 113 💬 |
219 | Adeno-associated virus serotype hu68 containing the human GALC gene | - | - | - | - | 1件: 19 19 💬 |
220 | Adeno-associated virus serotype rh.10 expressing beta-galactosidase | 1件: Tilactase Tilactase | 1件: Lactase
Lactase
💬 | - | - | 1件: 19 19 💬 |
221 | ADENO-ASSOCIATED VIRUS SEROTYPE RH74 CONTAINING THE HUMAN MICRO-DYSTROPHIN GENE | - | - | - | - | 1件: 113 113 💬 |
222 | Adeno-associated virus type 2 vector encoding Rab escort protein 1 | - | - | - | - | 1件: 90 90 💬 |
223 | Adeno-associated virus-CFTR vector | - | - | - | - | 1件: 299 299 💬 |
224 | Adenoviral Vector-Mediated Gene Transfer | - | - | - | - | 1件: 251 251 💬 |
225 | Adipose-derived stromal vascular fraction cells | - | - | - | - | 1件: 6 6 💬 |
226 | ADS-001 | - | - | - | - | 1件: 231 231 💬 |
227 | Advagraf 0,5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
228 | ADVM-043 | - | - | - | - | 1件: 231 231 💬 |
229 | AEGR-733 | - | - | - | - | 1件: 79 79 💬 |
230 | AEZS-130 (formerly ARD-07) | - | - | - | - | 1件: 78 78 💬 |
231 | AGM 719 | - | - | - | - | 1件: 46 46 💬 |
232 | Agrippal S1 (Influenza vaccination) | - | - | - | - | 1件: 46 46 💬 |
233 | AGS-009 | - | - | - | - | 1件: 49 49 💬 |
234 | AIN457, 75 mg | - | - | - | - | 1件: 271 271 💬 |
235 | AK106-001616 | 1件: AK106-001616 AK106-001616 | - | - | - | 1件: 46 46 💬 |
236 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
237 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
238 | Alendronate versus alfacalcidol (1-alpha OH vitamin D) | 3件: Alendronic acid Alendronic acid, Alfacalcidol, Vitamin D | 2件: Alfacalcidol
Alfacalcidol
,
Alendronic acid
💬 | 2件: FDPS FDPS, VDR 💬 | 9件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Terpenoid backbone biosynthesis, Tuberculosis 💬 | 3件: 41 41, 46, 50 💬 |
239 | ALK-001 | - | - | - | - | 1件: 301 301 💬 |
240 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
241 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
242 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
243 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
244 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
245 | ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED | - | - | - | - | 1件: 90 90 💬 |
246 | ALN-77412 | - | - | - | - | 1件: 231 231 💬 |
247 | Aloe vera | 1件: Aloe vera leaf Aloe vera leaf | - | - | - | 2件: 97 97, 226 💬 |
248 | Aloe vera gel | 1件: Aloe vera leaf Aloe vera leaf | - | - | - | 1件: 97 97 💬 |
249 | ALRN-5281 0.015 mg/kg | - | - | - | - | 1件: 78 78 💬 |
250 | ALRN-5281 0.05 mg/kg | - | - | - | - | 1件: 78 78 💬 |
251 | ALRN-5281 0.15 mg/kg | - | - | - | - | 1件: 78 78 💬 |
252 | ALX-0061 | - | - | - | - | 2件: 46 46, 49 💬 |
253 | ALX-0061 150 mg/mL | - | - | - | - | 1件: 49 49 💬 |
254 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
255 | ALX-0081 | - | - | - | - | 1件: 64 64 💬 |
256 | ALX-009 | - | - | - | - | 1件: 299 299 💬 |
257 | ALX-0600 | - | - | - | - | 1件: 96 96 💬 |
258 | ALXN2040 (ACH-0144471) | - | - | - | - | 1件: 62 62 💬 |
259 | AM-01 | - | - | - | - | 1件: 51 51 💬 |
260 | AMB-05X | - | - | - | - | 1件: 85 85 💬 |
261 | AMG 714 | - | - | - | - | 1件: 46 46 💬 |
262 | AMG 719 | - | - | - | - | 1件: 46 46 💬 |
263 | AMG 785 | - | - | - | - | 1件: 274 274 💬 |
264 | AMG 827 70 mg | - | - | - | - | 1件: 46 46 💬 |
265 | AMG 827 700 MG | - | - | - | - | 1件: 96 96 💬 |
266 | ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | - | - | - | - | 1件: 156 156 💬 |
267 | ANAVEX2-73 | - | - | - | - | 2件: 6 6, 156 💬 |
268 | ANAVEX2-73 (blarcamesine) | 1件: Blarcamesine Blarcamesine | 1件: Blarcamesine
Blarcamesine
💬 | 6件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SIGMAR1 💬 | 14件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 156 156 💬 |
269 | ANAVEX2-73 oral liquid | - | - | - | - | 1件: 156 156 💬 |
270 | Angiotensin-(1-7) | 1件: Angiotensin II Angiotensin II | 2件: Angiotensin II
Angiotensin II
,
Angiotensin II
💬 | 2件: AGTR1 AGTR1, AGTR2 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
271 | ANK-700 | - | - | - | - | 1件: 13 13 💬 |
272 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 💬 |
273 | Anti-IL-20 (109-0012) | 1件: Fletikumab Fletikumab | 1件: Fletikumab
Fletikumab
💬 | 1件: IL20 IL20 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
274 | Anti-pandemic H1N1 influenza vaccine | - | - | - | - | 6件: 46 46, 49, 50, 51, 53, 107 💬 |
275 | Anti-von Willebrand Factor Nanobody | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 💬 |
276 | Anti-von Willebrand Factor Nanobody, Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
277 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
278 | ANTOX (vers) 1.2 | - | - | - | - | 1件: 298 298 💬 |
279 | ANTOX (vers.)1.2 | - | - | - | - | 1件: 298 298 💬 |
280 | Antox version 1.2 | - | - | - | - | 1件: 298 298 💬 |
281 | AODG (Apigenin-7-O-glucuronide) | 1件: Apigenin Apigenin | - | - | - | 1件: 97 97 💬 |
282 | Apomorphine 0.25% (2.5mg/ml) | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
283 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
284 | Apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side | 1件: Sinecatechins Sinecatechins | 1件: Sinecatechins
Sinecatechins
💬 | - | - | 1件: 160 160 💬 |
285 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: Apraclonidine
Apraclonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
286 | Apriso 0.375G ER CAP | - | - | - | - | 1件: 97 97 💬 |
287 | ARCT-032 | - | - | - | - | 1件: 299 299 💬 |
288 | Arikayce™ 70 mg | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
289 | ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
290 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
291 | Ascorbic acid (Vitamin C) | 1件: Ascorbic acid Ascorbic acid | 1件: Ascorbic acid
Ascorbic acid
💬 | - | - | 1件: 10 10 💬 |
292 | Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E) | 3件: Ascorbic acid Ascorbic acid, Tocopherol, Vitamin E | 3件: Ascorbic acid
Ascorbic acid
,
Vitamin E
,
Tocopherol
💬 | - | - | 1件: 206 206 💬 |
293 | Ascorbic acid vit C | 1件: Ascorbic acid Ascorbic acid | 1件: Ascorbic acid
Ascorbic acid
💬 | - | - | 1件: 10 10 💬 |
294 | ASF-1096 Cream 0.25% | - | - | - | - | 1件: 49 49 💬 |
295 | ASF-1096 Cream 0.5% | - | - | - | - | 1件: 49 49 💬 |
296 | ASF-1096 Cream 1.0% | - | - | - | - | 1件: 49 49 💬 |
297 | ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
298 | Atacicept 75 mg | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 13 13, 49, 66 💬 |
299 | Atacicept 75 milligram (mg) | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
300 | ATYR1923 1.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
301 | ATYR1923 3.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
302 | ATYR1923 5.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
303 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
304 | Autologous ADIpose derived stromal vascular fraction | - | - | - | - | 1件: 96 96 💬 |
305 | Autologous cardiac stem cells (JRM-001) | - | - | - | - | 2件: 210 210, 211 💬 |
306 | Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene | - | - | - | - | 1件: 65 65 💬 |
307 | AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
308 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING THE HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 💬 |
309 | Autologous CD34+ cells transduced with a lentiviral vector encoding the ARSA cDNA | - | - | - | - | 1件: 19 19 💬 |
310 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTI-D VECTOR ENCODING ABCD1 CDNA | - | - | - | - | 1件: 20 20 💬 |
311 | Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy | - | - | - | - | 1件: 65 65 💬 |
312 | Autologous CD34+ cells transduced with WASP lentiviral vector | - | - | - | - | 1件: 65 65 💬 |
313 | Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence | - | - | - | - | 1件: 65 65 💬 |
314 | Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII | - | - | - | - | 1件: 19 19 💬 |
315 | Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene | - | - | - | - | 1件: 65 65 💬 |
316 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
317 | Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope | - | - | - | - | 1件: 13 13 💬 |
318 | Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV) | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
319 | Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA | - | - | - | - | 1件: 20 20 💬 |
320 | Autologous Stromal Vascular Fraction (SVF) | - | - | - | - | 1件: 85 85 💬 |
321 | Autologous stromal vascular fraction cells | - | - | - | - | 1件: 46 46 💬 |
322 | Autologous Tissue-Engineered Vascular Graft | - | - | - | - | 1件: 210 210 💬 |
323 | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
324 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
325 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
326 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
327 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
328 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
329 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
330 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
331 | AVR-RD-01 | - | - | - | - | 1件: 19 19 💬 |
332 | AVR-RD-02 | - | - | - | - | 1件: 19 19 💬 |
333 | AZLI 75 mg three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
334 | AZLI 75 mg three times daily (TID) | - | - | - | - | 1件: 299 299 💬 |
335 | AZLI 75 mg two times a day (BID)/ three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
336 | AZLI 75 mg two times a day (BID)/three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
337 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 💬 |
338 | Bacille Calmette-Guerin vaccine | - | - | - | - | 1件: 13 13 💬 |
339 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 💬 |
340 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
341 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 💬 |
342 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 💬 |
343 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 💬 |
344 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 💬 |
345 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 💬 |
346 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
347 | BAY 59-7939 | - | - | - | - | 1件: 210 210 💬 |
348 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 💬 |
349 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 💬 |
350 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
351 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
352 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
353 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 💬 |
354 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
355 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
356 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 💬 |
357 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 💬 |
358 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 💬 |
359 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
360 | BAY 79-4998 | - | - | - | - | 1件: 13 13 💬 |
361 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
362 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 💬 |
363 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 💬 |
364 | BCD-055 | - | - | - | - | 2件: 46 46, 271 💬 |
365 | BCD-063 | - | - | - | - | 1件: 13 13 💬 |
366 | BCD-085 | - | - | - | - | 2件: 93 93, 271 💬 |
367 | BCD-089 | - | - | - | - | 1件: 46 46 💬 |
368 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 💬 |
369 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 💬 |
370 | BCG TICE Vaccine | - | - | - | - | 1件: 299 299 💬 |
371 | BCG20-0134 | - | - | - | - | 1件: 13 13 💬 |
372 | Bee venom | - | - | - | - | 1件: 6 6 💬 |
373 | Belimumab plus Early Vaccination | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
374 | Belimumab plus Late Vaccination | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
375 | Benazepril, Valsartan and Fluvastatin | 3件: Benazepril Benazepril, Fluvastatin, Valsartan | 3件: Valsartan
Valsartan
,
Benazepril
,
Fluvastatin
💬 | 3件: ACE ACE, AGTR1, HMGCR 💬 | 22件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 218 218 💬 |
376 | BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 53 53 💬 |
377 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
378 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
379 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
380 | Betaloc ZOK 25, 23,75 mg | - | - | - | - | 1件: 113 113 💬 |
381 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 💬 |
382 | BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
383 | BGP-014 | - | - | - | - | 1件: 97 97 💬 |
384 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 💬 |
385 | BGX-0214 | - | - | - | - | 1件: 46 46 💬 |
386 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 💬 |
387 | BHT-3009-01 | - | - | - | - | 1件: 13 13 💬 |
388 | BHV-0223 | - | - | - | - | 1件: 2 2 💬 |
389 | BHV3241, verdiperstat | 1件: Verdiperstat Verdiperstat | 1件: Verdiperstat
Verdiperstat
💬 | 1件: MPO MPO 💬 | 5件: Acute myeloid leukemia Acute myeloid leukemia, Drug metabolism - other enzymes, Neutrophil extracellular trap formation, Phagosome, Transcriptional misregulation in cancer 💬 | 1件: 17 17 💬 |
390 | BI 705564 | - | - | - | - | 1件: 49 49 💬 |
391 | BI 706321 | - | - | - | - | 1件: 96 96 💬 |
392 | BI 730357 | - | - | - | - | 1件: 271 271 💬 |
393 | BI 764198 | - | - | - | - | 1件: 222 222 💬 |
394 | BIBR 796 BS | - | - | - | - | 1件: 46 46 💬 |
395 | BIBR 796 BS, 20 mg | - | - | - | - | 1件: 96 96 💬 |
396 | BIBR 796 BS, 5 mg | - | - | - | - | 1件: 96 96 💬 |
397 | BIIB 017 | - | - | - | - | 1件: 13 13 💬 |
398 | BIIB050 / KNS-760704 | - | - | - | - | 1件: 2 2 💬 |
399 | BIIB050/KNS-760704 | - | - | - | - | 1件: 2 2 💬 |
400 | Biological/Vaccine: Allogeneic HB-adMSCs | 1件: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins | - | - | - | 1件: 6 6 💬 |
401 | BIRB 796 BS, high dose | - | - | - | - | 1件: 46 46 💬 |
402 | BIRB 796 BS, low dose | - | - | - | - | 1件: 46 46 💬 |
403 | BIRT 2584 XX | - | - | - | - | 1件: 13 13 💬 |
404 | BIVV001 (rFVIIIFc-VWF-XTEN) | - | - | - | - | 1件: 288 288 💬 |
405 | BL-7040 | - | - | - | - | 1件: 97 97 💬 |
406 | Blood coagulation Factor VIII and vWF, human | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
407 | Blood coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 💬 |
408 | BMN 044 | - | - | - | - | 1件: 113 113 💬 |
409 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
410 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
411 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
412 | BMN 045 | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
413 | BMN 053 | - | - | - | - | 1件: 113 113 💬 |
414 | BMN 701 | - | - | - | - | 1件: 256 256 💬 |
415 | BMS-986004 75 mg IV | - | - | - | - | 1件: 63 63 💬 |
416 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
417 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
418 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
419 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
420 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
421 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
422 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
423 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
424 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
425 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
426 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
427 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
428 | Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof | - | - | - | - | 1件: 107 107 💬 |
429 | Boost VHC | - | - | - | - | 1件: 299 299 💬 |
430 | Bortezomib (Velcade®) | 1件: Bortezomib Bortezomib | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 66 66 💬 |
431 | Botulinum toxin type B (2500 units / vial) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 💬 |
432 | Botulinum Toxin: Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
433 | BPLG-003 | - | - | - | - | 1件: 78 78 💬 |
434 | Brentuximab vedotin | 1件: Brentuximab vedotin Brentuximab vedotin | 1件: Brentuximab vedotin
Brentuximab vedotin
💬 | 10件: TNFRSF8 TNFRSF8, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 11件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 49 49, 51 💬 |
435 | BRL-049653 | - | - | - | - | 1件: 46 46 💬 |
436 | Broncho-Vaxom | 1件: OM85 OM85 | - | - | - | 1件: 85 85 💬 |
437 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 💬 |
438 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
439 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
440 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
441 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
442 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
443 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
444 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
445 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 💬 |
446 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 💬 |
447 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 3件: Epinephrine
Epinephrine
,
Clonidine
,
Bupivacaine
💬 | 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬 |
448 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
449 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 💬 |
450 | C-028380 | - | - | - | - | 1件: 106 106 💬 |
451 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
452 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
453 | Calcium and Vit D | 1件: Calcium Calcium | - | - | - | 1件: 49 49 💬 |
454 | Calcium and Vitamin D combination | 2件: Calcium Calcium, Vitamin D | - | - | - | 1件: 13 13 💬 |
455 | Calcium Citrate with Vitamin D2 | 3件: Calcium Calcium, Calcium citrate, Ergocalciferol | 2件: Ergocalciferol
Ergocalciferol
,
Calcium citrate
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 84 84 💬 |
456 | CALY-002 | - | - | - | - | 1件: 98 98 💬 |
457 | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | - | - | - | - | 1件: 107 107 💬 |
458 | Cannabidiol vaginal suppository | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 226 226 💬 |
459 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
460 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
461 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
462 | Capsaicin vapor | 1件: Capsaicin Capsaicin | 1件: Capsaicin
Capsaicin
💬 | 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
463 | CARBONE VEGETALE | - | - | - | - | 1件: 13 13 💬 |
464 | Carbone vegetale polvere | - | - | - | - | 1件: 13 13 💬 |
465 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
466 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
467 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 💬 |
468 | Catapresan 75 | - | - | - | - | 1件: 78 78 💬 |
469 | Catapresan 75, Tabletten | - | - | - | - | 1件: 65 65 💬 |
470 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
471 | Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
472 | CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
473 | CB-01-02 | - | - | - | - | 1件: 97 97 💬 |
474 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 💬 |
475 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
476 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
477 | CCI-779 | - | - | - | - | 2件: 13 13, 46 💬 |
478 | CCP-020 | - | - | - | - | 1件: 36 36 💬 |
479 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 💬 |
480 | CE-VST01-JC | 1件: CE-VST01-JC CE-VST01-JC | - | - | - | 1件: 25 25 💬 |
481 | Ceftazidim Fresenius Kabi 2000 mg poeder voor oplossing voor injectie of infusie | 1件: Ceftazidime Ceftazidime | 2件: Ceftazidime
Ceftazidime
,
Ceftazidime
💬 | - | - | 1件: 299 299 💬 |
482 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
483 | CER-001 | - | - | - | - | 1件: 79 79 💬 |
484 | CERC-006 | - | - | - | - | 1件: 278 278 💬 |
485 | CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | - | - | - | - | 1件: 6 6 💬 |
486 | CERE-120: Adeno-Associated Virus Delivery of Neurturin | - | - | - | - | 1件: 6 6 💬 |
487 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
488 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
489 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
490 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
491 | Cervarix suspensie voor injectie | 4件: Human papillomavirus type 16 L1 capsid protein antigen Human papillomavirus type 16 L1 capsid protein antigen, Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen, Human papillomavirus type 18 L1 capsid protein antigen, Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen | - | - | - | 3件: 49 49, 50, 107 💬 |
492 | CGP 77116 | - | - | - | - | 1件: 13 13 💬 |
493 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 💬 |
494 | Cholecalciferol (Vitamin D3) | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 13 13, 299 💬 |
495 | Cholecalciferol (vitaminD3) | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
496 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
497 | Cholecalciferol and C. Xanthorrhiza | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
498 | Cholecalciferol, Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 💬 |
499 | CHS-0214 | - | - | - | - | 1件: 46 46 💬 |
500 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
501 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
502 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
503 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
504 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
505 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 💬 |
506 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
507 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 💬 |
508 | CLORURO SODICO 7% | - | - | - | - | 1件: 299 299 💬 |
509 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 💬 |
510 | CNSA-001 | - | - | - | - | 1件: 240 240 💬 |
511 | CNT-02 | - | - | - | - | 1件: 160 160 💬 |
512 | Coagulación factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
513 | Coagulation factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
514 | Coagulation factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
515 | Coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
516 | Coenzyme Q10 with vitamin E | 2件: Ubidecarenone Ubidecarenone, Vitamin E | 2件: Ubidecarenone
Ubidecarenone
,
Vitamin E
💬 | - | - | 1件: 6 6 💬 |
517 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 💬 |
518 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
519 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 💬 |
520 | COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin | - | - | - | - | 1件: 36 36 💬 |
521 | Colecalciferol D3 (Vigantol Oil) | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
522 | Colistimethate 75 mg inhaled two times daily | 1件: Colistimethate Colistimethate | - | - | - | 1件: 299 299 💬 |
523 | Combination Product: L-dopa 70mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
524 | Combination Product: L-dopa 70mg/carbidopa 7mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
525 | Combination Product: Treprostinil via implanted pump | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
526 | Combination therapy with vigabatrin and prednisolone | 2件: Prednisolone Prednisolone, Vigabatrin | 2件: Prednisolone
Prednisolone
,
Vigabatrin
💬 | 2件: ABAT ABAT, NR3C1 💬 | 8件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 💬 |
527 | Commercial Ventavis® (iloprost) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
528 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
529 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
530 | Conjugated pneumococcal vaccine (Prevenar) | - | - | - | - | 1件: 65 65 💬 |
531 | Contrast Enhanced Voiding Urosonography with Urodynamic Testing | - | - | - | - | 1件: 118 118 💬 |
532 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 💬 |
533 | COR-003 | - | - | - | - | 1件: 75 75 💬 |
534 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
535 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
536 | Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin | 2件: Tetracosactide Tetracosactide, Vigabatrin | 2件: Cosyntropin
Cosyntropin
,
Vigabatrin
💬 | 2件: ABAT ABAT, MC2R 💬 | 12件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, cAMP signaling pathway 💬 | 1件: 145 145 💬 |
537 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 💬 |
538 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
539 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
540 | COVID-19 vaccination | - | - | - | - | 1件: 13 13 💬 |
541 | COVID-19 vaccine | - | - | - | - | 3件: 46 46, 49, 51 💬 |
542 | COVID-19 vaccine (Ad26.COV2-S [recombinant]) | - | - | - | - | 1件: 299 299 💬 |
543 | COVID-19 Vaccine (ChAdOx1-S [recombinant]) | - | - | - | - | 3件: 46 46, 51, 299 💬 |
544 | COVID-19 Vaccine AstraZeneca | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 53 💬 |
545 | COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
546 | COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 53 53 💬 |
547 | Covid-19 Vaccine Janssen | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 2件: 53 53, 299 💬 |
548 | COVID-19 Vaccine Janssen suspension for injection | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 1件: 299 299 💬 |
549 | COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 2件: 53 53, 299 💬 |
550 | COVID-19 Vaccine Moderna | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 4件: 46 46, 51, 65, 299 💬 |
551 | COVID-19 Vaccine Moderna dispersion for injection | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 299 299 💬 |
552 | COVID19 vaccine | - | - | - | - | 1件: 13 13 💬 |
553 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 💬 |
554 | CRD-TMH-001 | - | - | - | - | 1件: 113 113 💬 |
555 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
556 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
557 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
558 | Creon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
559 | CRx-102 (2.7/180) | - | - | - | - | 1件: 46 46 💬 |
560 | CRx-102 (2.7/360) | - | - | - | - | 1件: 46 46 💬 |
561 | CRYOPRESERVED AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 💬 |
562 | Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
563 | CS-0777 tablets | - | - | - | - | 1件: 13 13 💬 |
564 | CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST) | - | - | - | - | 1件: 19 19 💬 |
565 | Cudetaxestat (BLD-0409) | - | - | - | - | 1件: 85 85 💬 |
566 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
567 | CVL-751 | - | - | - | - | 1件: 6 6 💬 |
568 | CVXL-0107 | - | - | - | - | 1件: 6 6 💬 |
569 | CX-016492 | - | - | - | - | 1件: 245 245 💬 |
570 | CX-017950 | - | - | - | - | 1件: 245 245 💬 |
571 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 💬 |
572 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
573 | CYCLOSPORINE VS INFLIXIMAB | 2件: Cyclosporine Cyclosporine, Infliximab | 2件: Cyclosporine
Cyclosporine
,
Infliximab
💬 | 6件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, TNF 💬 | 86件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Dopaminergic synapse, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Glucagon signaling pathway, Glutamatergic synapse, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Renin secretion, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, VEGF signaling pathway, Viral protein interaction with cytokine and cytokine receptor, Wnt signaling pathway, Yersinia infection, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
574 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
575 | Cysteamine (mercaptamine) viscous solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
576 | Cytokine-treated Veto Cells | - | - | - | - | 1件: 60 60 💬 |
577 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
578 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
579 | D.3.6.2.1 - valore: 45 / 0.45 mg/ml | - | - | - | - | 1件: 97 97 💬 |
580 | D.3.6.2.1 - valore: 5 o 10 mg/kg | - | - | - | - | 1件: 97 97 💬 |
581 | D3 VitaCaps® | - | - | - | - | 2件: 96 96, 97 💬 |
582 | DAS-001 | - | - | - | - | 1件: 11 11 💬 |
583 | DaTSCAN 74 MBq/ml solution for injection | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
584 | Dekristol 20.000 ie | - | - | - | - | 1件: 96 96 💬 |
585 | Delayed Release 6MP or Calcitriol vs. Purinethol | 1件: Calcitriol Calcitriol | 1件: Calcitriol
Calcitriol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
586 | Depot leuprolide acetate 3.75 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 51 51 💬 |
587 | Descartes-08 | - | - | - | - | 1件: 11 11 💬 |
588 | Desert Harvest Aloe Vera Capsules | 1件: Aloe vera leaf Aloe vera leaf | - | - | - | 1件: 226 226 💬 |
589 | Desmotabs® 0,2 mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
590 | Desmotabs® 0,2mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
591 | Dexamethasone 0,1 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
592 | Dexamethasone 0,5mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
593 | Dexamethasone 0.5mg Tablet | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
594 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
595 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
596 | Dietary supplement omega3 fatty acids aand vitamins | - | - | - | - | 1件: 46 46 💬 |
597 | Digoxin 0.25 mg | 1件: Digoxin Digoxin | 1件: Digoxin
Digoxin
💬 | 4件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4 💬 | 18件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
598 | Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias) | 1件: Amiodarone Amiodarone | 1件: Amiodarone
Amiodarone
💬 | 16件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 32件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 28 28 💬 |
599 | Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG | 2件: Amiodarone Amiodarone, Epigallocatechin gallate | 1件: Amiodarone
Amiodarone
💬 | 16件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 32件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 28 28 💬 |
600 | DIURF-006 | - | - | - | - | 1件: 81 81 💬 |
601 | DNS-7801 (high dose) | - | - | - | - | 1件: 6 6 💬 |
602 | DNS-7801 (low-dose) | - | - | - | - | 1件: 6 6 💬 |
603 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: Gadoteric acid
Gadoteric acid
💬 | - | - | 1件: 13 13 💬 |
604 | DPA-714 PET/MRI | - | - | - | - | 1件: 13 13 💬 |
605 | DPA-714-PET/MRI | - | - | - | - | 1件: 6 6 💬 |
606 | Drug-Carbamazepine (Tegretol XR) | 1件: Carbamazepine Carbamazepine | 1件: Carbamazepine
Carbamazepine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 231 231 💬 |
607 | DS-7011a | - | - | - | - | 1件: 49 49 💬 |
608 | Dulaglutide 0.75Mg/0.5Ml Inj Pen | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
609 | Dummy Qing Re Huo Xue (QRHX) | - | - | - | - | 1件: 46 46 💬 |
610 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 💬 |
611 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
612 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | 1件: 63 63 💬 |
613 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
614 | Early Harvest Extra Virgin Olive Oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: Olive oil
Olive oil
💬 | - | - | 1件: 13 13 💬 |
615 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 💬 |
616 | EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
617 | EF1aS-ADA lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
618 | Efexor XL 75 mg | - | - | - | - | 1件: 46 46 💬 |
619 | Efexor XL 75 mg (venlafaxine) | 1件: Venlafaxine Venlafaxine | 1件: Venlafaxine
Venlafaxine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
620 | EGB 761 (r) 120 mg | - | - | - | - | 1件: 18 18 💬 |
621 | EGb 761 120 mg | - | - | - | - | 1件: 18 18 💬 |
622 | EGb 761® (Tanakan®) | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 13 13 💬 |
623 | Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening | 3件: Elexacaftor Elexacaftor, Ivacaftor, Tezacaftor | 3件: Ivacaftor
Ivacaftor
,
Tezacaftor
,
Elexacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
624 | Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM] | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
625 | ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) | - | - | - | - | 1件: 299 299 💬 |
626 | ELX-02 | 1件: ELX-02 ELX-02 | - | - | - | 3件: 19 19, 218, 299 💬 |
627 | EMEA/H/C/000109 | - | - | - | - | 1件: 203 203 💬 |
628 | EMEA/H/C/000125 | - | - | - | - | 1件: 299 299 💬 |
629 | EMEA/H/C/000240 | - | - | - | - | 2件: 96 96, 97 💬 |
630 | EMEA/H/C/000481 | - | - | - | - | 1件: 97 97 💬 |
631 | EMEA/H/C/000638 | - | - | - | - | 1件: 113 113 💬 |
632 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 💬 |
633 | EMEA/H/C/000712 | - | - | - | - | 1件: 227 227 💬 |
634 | EMEA/H/C/002576 | - | - | - | - | 1件: 96 96 💬 |
635 | EMEA/H/C/002778 | - | - | - | - | 1件: 96 96 💬 |
636 | EMEA/H/C/004214 | - | - | - | - | 1件: 46 46 💬 |
637 | EMSELEX 7,5 mg Retardtabletten | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
638 | ENALAPRIL VALSARTAN METHYLPREDNISONE | 3件: Enalapril Enalapril, Methylprednisone, Valsartan | 2件: Valsartan
Valsartan
,
Enalapril
💬 | 2件: ACE ACE, AGTR1 💬 | 18件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
639 | ENB-0040 | - | - | - | - | 1件: 172 172 💬 |
640 | ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
641 | ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
642 | ENBREL*SC 4SIR 25MG 0,5ML+8TAM | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
643 | ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA | - | - | - | - | 1件: 51 51 💬 |
644 | ENDOPROST 0,05MG/0,5ML 1F | - | - | - | - | 1件: 51 51 💬 |
645 | ENDOPROST 50*INFUS 1F 0,050MG/ | - | - | - | - | 1件: 51 51 💬 |
646 | Engensis (VM202) | - | - | - | - | 1件: 10 10 💬 |
647 | ENOS transfected EPCs will be delivered via a PA line | - | - | - | - | 1件: 86 86 💬 |
648 | ENT-01 | - | - | - | - | 1件: 6 6 💬 |
649 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
650 | ENTYVIO - 300 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
651 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 💬 |
652 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
653 | Epaxal Berna (virosomal hepatitis A vaccine) | 1件: Hepatitis A Vaccine Hepatitis A Vaccine | - | - | - | 2件: 96 96, 97 💬 |
654 | EPI-743 | - | - | - | - | 3件: 21 21, 156, 337 💬 |
655 | EPI-743 200mg | - | - | - | - | 1件: 6 6 💬 |
656 | EPI-743 400mg | - | - | - | - | 1件: 6 6 💬 |
657 | ERB-041 | - | - | - | - | 3件: 46 46, 96, 226 💬 |
658 | Ergocalciferol (vitamin D2) | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
659 | Essential amino acid intake + Leucine vs total AA supplement | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 299 299 💬 |
660 | Estradiol valerate | 2件: Estradiol Estradiol, Estradiol valerate | 2件: Estradiol
Estradiol
,
Estradiol valerate
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 65 65 💬 |
661 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
662 | Etanercept via Autoinjector A | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
663 | Etanercept via Autoinjector B | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
664 | ETHNODYNE VISIO | - | - | - | - | 1件: 6 6 💬 |
665 | ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
666 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
667 | EU/1/03/256/001 | - | - | - | - | 1件: 107 107 💬 |
668 | EU/1/03/268/002 | - | - | - | - | 1件: 96 96 💬 |
669 | EU/1/06/362/003: 5µg (1 pen) | - | - | - | - | 1件: 193 193 💬 |
670 | EU/1/07/389/001 | - | - | - | - | 1件: 107 107 💬 |
671 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 💬 |
672 | EU/1/14/980/002 | - | - | - | - | 1件: 269 269 💬 |
673 | EU/1/14/980/003 | - | - | - | - | 1件: 269 269 💬 |
674 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 💬 |
675 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 💬 |
676 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 💬 |
677 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 💬 |
678 | EU/1/99/116/003 | - | - | - | - | 1件: 96 96 💬 |
679 | EU/1/99/126/001 | - | - | - | - | 1件: 107 107 💬 |
680 | EU/1/99/126/017 | - | - | - | - | 1件: 46 46 💬 |
681 | EU/1/99/126/020 | - | - | - | - | 1件: 46 46 💬 |
682 | EU1/97/031-032 | - | - | - | - | 1件: 18 18 💬 |
683 | EU1/97/031/031-032 | - | - | - | - | 1件: 18 18 💬 |
684 | EUR-1008 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
685 | EVP-0334 | - | - | - | - | 1件: 127 127 💬 |
686 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 💬 |
687 | EX VIVO CULTURED HUMAN MESENCHYMAL STEM CELLS | - | - | - | - | 2件: 51 51, 107 💬 |
688 | Ex vivo immunotherapy | - | - | - | - | 1件: 60 60 💬 |
689 | Ex-vivo approach concerning 25 patients | - | - | - | - | 2件: 102 102, 299 💬 |
690 | Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA. | - | - | - | - | 1件: 36 36 💬 |
691 | Ex-vivo gene-therapy | - | - | - | - | 1件: 65 65 💬 |
692 | Exelon 3,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
693 | Exelon 6,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
694 | Extra Virgin Olive Oil (EVOO) | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: Olive oil
Olive oil
💬 | - | - | 1件: 49 49 💬 |
695 | Factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
696 | Factor VIII concentrate | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
697 | Factor von Willebrand | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
698 | FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
699 | Factor XIIa antagonist monoclonal antibody | - | - | - | - | 1件: 85 85 💬 |
700 | Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 3件: 51 51, 97, 288 💬 |
701 | Factor XIII Concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
702 | Factor XIII Concentrate (Human), Pasteurized | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
703 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: Fasudil
Fasudil
💬 | 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
704 | FCX-007 | - | - | - | - | 1件: 36 36 💬 |
705 | FCX-013 | - | - | - | - | 1件: 51 51 💬 |
706 | Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
707 | FG-3019 10mg/mL in 10 mL vials | - | - | - | - | 1件: 85 85 💬 |
708 | Fibrogammin®P, coagulation factor XIII concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 💬 |
709 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
710 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
711 | FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | 1件: Amifampridine Amifampridine | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 💬 |
712 | FLUDARABINA ACCORD - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 5 FLACONCINI IN VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 19 19 💬 |
713 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
714 | FLX-787-ODT | - | - | - | - | 1件: 2 2 💬 |
715 | FLX-787-ODT (orally disintegrating tablet) | - | - | - | - | 1件: 10 10 💬 |
716 | FLX-787-ODT (orally disintigrating tablet) | - | - | - | - | 1件: 2 2 💬 |
717 | Focetria (Monovalent MF59-Adjuvanted vaccine) | - | - | - | - | 3件: 46 46, 49, 271 💬 |
718 | Folic Acid, Vitamin B6, Vitamin B12 | 3件: Cyanocobalamin Cyanocobalamin, Folic acid, Pyridoxine | 6件: Folic acid
Folic acid
,
Cyanocobalamin
,
Cyanocobalamin Co 57
,
Cyanocobalamin Co 58
,
Cyanocobalamin Co 60
,
Pyridoxine
💬 | - | - | 1件: 6 6 💬 |
719 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 💬 |
720 | FP-CYA-050 | - | - | - | - | 1件: 97 97 💬 |
721 | FP-CYA-053 | - | - | - | - | 1件: 97 97 💬 |
722 | FRM-0334 | - | - | - | - | 1件: 127 127 💬 |
723 | Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the a-L-iduronidase cDNA, in their final formulation medium. | - | - | - | - | 1件: 19 19 💬 |
724 | GA-GCB (velaglucerase alfa) | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
725 | Gaboxadol (HLX-0206) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
726 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
727 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
728 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
729 | Gadovist 1.0 mmol/ml Injektionslösung | 1件: Gadobutrol Gadobutrol | 1件: Gadobutrol
Gadobutrol
💬 | - | - | 1件: 13 13 💬 |
730 | GB-0998 | - | - | - | - | 1件: 50 50 💬 |
731 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 💬 |
732 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 💬 |
733 | GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
734 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
735 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
736 | GED-0301 | - | - | - | - | 2件: 96 96, 97 💬 |
737 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
738 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
739 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
740 | Gene activated human glucocerebrosidase, velaglucerase alfa | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
741 | Gene Therapy product:vMCO-I | - | - | - | - | 1件: 90 90 💬 |
742 | Gene Therapy-vMCO-010 | - | - | - | - | 1件: 301 301 💬 |
743 | Gene-Activated Human Glucocerebrosidase 200U/vial | - | - | - | - | 1件: 19 19 💬 |
744 | Gene-Activated Human Glucocerebrosidase 400U/vial | - | - | - | - | 1件: 19 19 💬 |
745 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 💬 |
746 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 💬 |
747 | Genotropin Mark VII pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
748 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
749 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
750 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 💬 |
751 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
752 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
753 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
754 | Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms | - | - | - | - | 1件: 11 11 💬 |
755 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 1件: Gentamicin
Gentamicin
💬 | - | - | 1件: 36 36 💬 |
756 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 💬 |
757 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
758 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
759 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
760 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
761 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
762 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
763 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
764 | GLWL-01 | - | - | - | - | 1件: 193 193 💬 |
765 | GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.) | - | - | - | - | 1件: 299 299 💬 |
766 | GNR-055 | - | - | - | - | 1件: 19 19 💬 |
767 | GNR-055 1.0-2.0-3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
768 | GNR-055 2.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
769 | GNR-055 3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
770 | GNR-069 | - | - | - | - | 1件: 63 63 💬 |
771 | Golimumab Final Vialed Product (FVP) | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
772 | Golimumab Liquid in Vial | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 97, 271 💬 |
773 | Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | 1件: Golodirsen Golodirsen | 1件: Golodirsen
Golodirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
774 | Graft-versus-tumor induction therapy | - | - | - | - | 2件: 60 60, 285 💬 |
775 | Group C meningococcal conjugate vaccine | - | - | - | - | 1件: 14 14 💬 |
776 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
777 | GW-1000-02 | - | - | - | - | 1件: 13 13 💬 |
778 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 💬 |
779 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
780 | H5.001CBCFTR | - | - | - | - | 1件: 299 299 💬 |
781 | Haemate P® (Human Coagulation Factor VIII) | 2件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
782 | HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 14 💬 |
783 | Haemophilus type b vaccine (conjugated) | - | - | - | - | 1件: 14 14 💬 |
784 | HBVAXPRO 5 micrograms/0.5 ml | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
785 | HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
786 | Hepatitis A Vaccine | 1件: Hepatitis A Vaccine Hepatitis A Vaccine | - | - | - | 3件: 46 46, 96, 97 💬 |
787 | Hepatitis A vaccine ( HAVRIX or EPAXAL) | 1件: Hepatitis A Vaccine Hepatitis A Vaccine | - | - | - | 1件: 46 46 💬 |
788 | Hepatitis A vaccine and tetanus vaccine | 1件: Hepatitis A Vaccine Hepatitis A Vaccine | - | - | - | 1件: 46 46 💬 |
789 | Hepatitis B Vaccine | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
790 | HEPATITIS B VACCINE (RDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
791 | HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN) | - | - | - | - | 1件: 46 46 💬 |
792 | Herpes Zoster Subunit (HZ/su) Vaccine | - | - | - | - | 1件: 49 49 💬 |
793 | Herpes Zoster Vaccine | - | - | - | - | 3件: 46 46, 96, 271 💬 |
794 | HGH-ViaDerm™ System (hGH or somatropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
795 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
796 | High dose ANAVEX2-73 | - | - | - | - | 1件: 6 6 💬 |
797 | High dose vehicle control | - | - | - | - | 1件: 46 46 💬 |
798 | High Dose-VIS649 | - | - | - | - | 1件: 66 66 💬 |
799 | High Phenolic Extra Virgin Olive Oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: Olive oil
Olive oil
💬 | - | - | 1件: 13 13 💬 |
800 | High-dose intravenous immunoglobulin (Venoglobulin-IH) | - | - | - | - | 1件: 51 51 💬 |
801 | High-dose vitamin D (2000 IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
802 | High-Dose Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
803 | HK-001 | - | - | - | - | 1件: 2 2 💬 |
804 | HL-085 | - | - | - | - | 1件: 34 34 💬 |
805 | HLADQA1*05A>G screening | - | - | - | - | 2件: 96 96, 97 💬 |
806 | HLB-001 | - | - | - | - | 1件: 246 246 💬 |
807 | HMPL-004 | - | - | - | - | 2件: 96 96, 97 💬 |
808 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
809 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
810 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
811 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
812 | HPV prophylactic vaccine Gardasil | 4件: Human papillomavirus type 11 L1 capsid protein antigen Human papillomavirus type 11 L1 capsid protein antigen, Human papillomavirus type 16 L1 capsid protein antigen, Human papillomavirus type 18 L1 capsid protein antigen, Human papillomavirus type 6 L1 capsid protein antigen | - | - | - | 1件: 49 49 💬 |
813 | HUMAN COAGULATION FACTOR VIII | 2件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
814 | Human coagulation Factor VIII / von Willebrand Factor | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
815 | Human coagulation factor VIII associated with Von Willebrand factor (VWF) | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
816 | Human Coagulation Factor VIII, Von Willebrand Factor | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
817 | HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND FACTOR COMPLEX | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
818 | HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND HUMAN COAGULATION FACTOR | 2件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
819 | Human Coagulation FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
820 | Human factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
821 | Human papillomavirus vaccination (Gardasil) | 4件: Human papillomavirus type 11 L1 capsid protein antigen Human papillomavirus type 11 L1 capsid protein antigen, Human papillomavirus type 16 L1 capsid protein antigen, Human papillomavirus type 18 L1 capsid protein antigen, Human papillomavirus type 6 L1 capsid protein antigen | - | - | - | 1件: 49 49 💬 |
822 | HUMAN VON WILLEBRAND FACTOR | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
823 | Human von Willebrand factor (VWF) and coagulation factor VIII (FVIII) | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
824 | Human VWF/FVIII concentrate | - | - | - | - | 1件: 288 288 💬 |
825 | Humanized anti-alpha v beta 6 mAb | - | - | - | - | 1件: 85 85 💬 |
826 | Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
827 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 💬 |
828 | Humira (adalimumab) 40 mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
829 | Humira (adalimumab) 40mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
830 | Humira (adalimumab) 40mg in 0.4ml s.c.injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
831 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
832 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
833 | HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
834 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
835 | Humira 40 mg injekcní roztok v predplnené injekcní stríkacce | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
836 | Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
837 | Humira 40 mg/0.8 ml solution for injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
838 | Humira 40 mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
839 | Humira 40mg/0.4ml pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
840 | Humira 40mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
841 | Humira 40mg/0.8ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
842 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
843 | Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
844 | Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
845 | HUMIRA*SC 2SIR+F 40MG 0,8ML+2T | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
846 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
847 | Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
848 | Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
849 | Hyperpolarized 129-Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
850 | Hyperpolarized Xe129 | - | - | - | - | 4件: 51 51, 85, 86, 299 💬 |
851 | Hyperpolarized Xenon | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
852 | Hyperpolarized Xenon 129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
853 | Hyperpolarized Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
854 | Hyperpolarized xenon-129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
855 | Hypertonic saline (7 %) and isotonic saline (0.9%) | - | - | - | - | 1件: 299 299 💬 |
856 | Hypertonic saline (7%) | - | - | - | - | 1件: 299 299 💬 |
857 | Hypertonic Saline 7% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
858 | I.v. immunoglobulins | - | - | - | - | 1件: 151 151 💬 |
859 | I.v. selexipag | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
860 | ICI 182,780 (Faslodex) | 1件: Fulvestrant Fulvestrant | 1件: Fulvestrant
Fulvestrant
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
861 | ICP-022 | - | - | - | - | 2件: 46 46, 49 💬 |
862 | ICX-RHY-013 | - | - | - | - | 1件: 36 36 💬 |
863 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
864 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
865 | IFB-088 | - | - | - | - | 1件: 2 2 💬 |
866 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
867 | Ig VENA | - | - | - | - | 2件: 50 50, 63 💬 |
868 | Ig VENA (10g/200mL) | - | - | - | - | 1件: 50 50 💬 |
869 | Ig VENA 100 ml vial | - | - | - | - | 1件: 63 63 💬 |
870 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 💬 |
871 | IGSC 20% daily push versus 2 times per week pump | - | - | - | - | 1件: 65 65 💬 |
872 | IGSC 20% daily push versus every 2 weeks pump | - | - | - | - | 1件: 65 65 💬 |
873 | IGSC 20% daily push versus once a week pump | - | - | - | - | 1件: 65 65 💬 |
874 | Iloprost (Ventavis BAYQ6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
875 | Iloprost (Ventavis inhaled, BAYQ6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
876 | Iloprost (Ventavis, BAYQ 6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
877 | Iloprost (Ventavis, BAYQ6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
878 | Iloprost (Ventavis®) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
879 | Iloprost Inhalation Solution (Ventavis) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 85 85, 86 💬 |
880 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
881 | Iloprost,(Ventavis, BAYQ6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
882 | ILV-094 | - | - | - | - | 1件: 46 46 💬 |
883 | IMCY-0141 | 1件: IMCY-0141 IMCY-0141 | - | - | - | 1件: 13 13 💬 |
884 | Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution | - | - | - | - | 1件: 63 63 💬 |
885 | Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution | - | - | - | - | 1件: 65 65 💬 |
886 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
887 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | 1件: 96 96 💬 |
888 | IMUKIN - 6 FLACONI 0.5 ML 100 MCG | - | - | - | - | 2件: 18 18, 58 💬 |
889 | IMUKIN*SC 6F 0,5ML 100MCG | - | - | - | - | 1件: 18 18 💬 |
890 | In-vitro approach concerning 25 patients | - | - | - | - | 2件: 102 102, 299 💬 |
891 | Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus | - | - | - | - | 1件: 53 53 💬 |
892 | Inactivated hepatitis A virus | - | - | - | - | 1件: 46 46 💬 |
893 | Inactivated Trivalent Influenza vaccine | - | - | - | - | 1件: 63 63 💬 |
894 | INALOSSIN - 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO BOMBOLA IN ALLUMINIO CON VALVOLA VI DA 20 LITRI | - | - | - | - | 1件: 294 294 💬 |
895 | INCB050465 0.3 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
896 | INCB050465 0.3mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
897 | INCB050465 1.0 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
898 | INCB050465 1.0mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
899 | IncobotulinumtoxinA (75 Units) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
900 | Infigratinib 0.016 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
901 | Infigratinib 0.032 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
902 | Infigratinib 0.064 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
903 | Infigratinib 0.128 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
904 | Infigratinib 0.25 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
905 | INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 56 56 💬 |
906 | Infliximab (BCD-055) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
907 | Infliximab 7 mg/kg every 8 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
908 | Infliximab and azathioprine combination at week 0 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
909 | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab | 5件: Adalimumab Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab | 5件: Adalimumab
Adalimumab
,
Infliximab
,
Golimumab
,
Vedolizumab
,
Ustekinumab
💬 | 6件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, TNF 💬 | 81件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
910 | Infliximab, adalimumab, golimumab, vedolizumab, ustekinumab | 5件: Adalimumab Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab | 5件: Adalimumab
Adalimumab
,
Infliximab
,
Golimumab
,
Vedolizumab
,
Ustekinumab
💬 | 6件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, TNF 💬 | 81件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
911 | Influenz virus surface antigens | - | - | - | - | 1件: 49 49 💬 |
912 | Influenza vaccination | - | - | - | - | 1件: 299 299 💬 |
913 | Influenza vaccine | - | - | - | - | 5件: 11 11, 13, 46, 51, 84 💬 |
914 | INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED) | - | - | - | - | 1件: 49 49 💬 |
915 | Influenza vaccine, Immune function | - | - | - | - | 1件: 107 107 💬 |
916 | Infudopa i.v. | - | - | - | - | 1件: 6 6 💬 |
917 | Infusion of ADR-001 (Mesenchymal stem cell) | - | - | - | - | 1件: 66 66 💬 |
918 | Inhaled 7% hypertonic saline (HS) | - | - | - | - | 1件: 299 299 💬 |
919 | Inhaled hypertonic saline (7%) | - | - | - | - | 1件: 299 299 💬 |
920 | Inhaled iloprost (Ventavis, BAYQ6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
921 | Inhaled nitric oxide 75 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 86 💬 |
922 | Inhaled Vancomycin | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 1件: 299 299 💬 |
923 | Inhaled VR040 | - | - | - | - | 1件: 6 6 💬 |
924 | Injection of autologous stromal vascular fraction | - | - | - | - | 1件: 51 51 💬 |
925 | INM-755 | - | - | - | - | 1件: 36 36 💬 |
926 | INM-755 (cannabinol) cream | 1件: Cannabinol Cannabinol | - | - | - | 1件: 36 36 💬 |
927 | INT-747 | - | - | - | - | 1件: 93 93 💬 |
928 | INT-747, OCA | - | - | - | - | 2件: 93 93, 94 💬 |
929 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
930 | Interleukin-7 | 1件: Interleukin-7 Interleukin-7 | - | - | - | 1件: 25 25 💬 |
931 | Intra venous injection of stem cell | - | - | - | - | 1件: 2 2 💬 |
932 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
933 | INZ-701 | - | - | - | - | 1件: 166 166 💬 |
934 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
935 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
936 | Irbesartan tablets (NDC# 31722-729-30 approved in the United states) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
937 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
938 | ISIS 703802 | - | - | - | - | 1件: 79 79 💬 |
939 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 💬 |
940 | Isotonic saline 0.9% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
941 | Itraconazole/voriconazole | 2件: Itraconazole Itraconazole, Voriconazole | 2件: Itraconazole
Itraconazole
,
Voriconazole
💬 | - | - | 1件: 299 299 💬 |
942 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
943 | IV vancomycin hydrochloride | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 1件: 299 299 💬 |
944 | Ivacaftor 25 mg/75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
945 | Ivacaftor 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
946 | Ivacaftor 75 mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
947 | IVACAFTOR 75mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
948 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬 |
949 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
950 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
951 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬 |
952 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
953 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
954 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
955 | JM-010 | - | - | - | - | 1件: 6 6 💬 |
956 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 💬 |
957 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 💬 |
958 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
959 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
960 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
961 | JNJ-72537634 | - | - | - | - | 1件: 97 97 💬 |
962 | JNJ-78934804 | - | - | - | - | 2件: 96 96, 97 💬 |
963 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
964 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
965 | JTE-051 | - | - | - | - | 1件: 46 46 💬 |
966 | KCT-0809 ophthalmic solution | - | - | - | - | 1件: 53 53 💬 |
967 | KINERET*SC 7SIR 100MG 0,67ML | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 28 28, 46, 107 💬 |
968 | KNS-760704 | - | - | - | - | 1件: 2 2 💬 |
969 | KPS-0373 | - | - | - | - | 1件: 18 18 💬 |
970 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
971 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
972 | Kreon 25 000 | - | - | - | - | 1件: 299 299 💬 |
973 | Kreon 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
974 | Kreon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
975 | KW-0761 | - | - | - | - | 1件: 26 26 💬 |
976 | KW-0761 0.3 mg/kg IV | - | - | - | - | 1件: 26 26 💬 |
977 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
978 | L-000124467 | - | - | - | - | 2件: 13 13, 46 💬 |
979 | L-000124467 (freebase) | - | - | - | - | 1件: 46 46 💬 |
980 | L-000124467-009J (succinat | - | - | - | - | 1件: 46 46 💬 |
981 | L-000883191 | - | - | - | - | 1件: 46 46 💬 |
982 | L-001069957 | - | - | - | - | 1件: 46 46 💬 |
983 | L03 AB 08 | - | - | - | - | 1件: 13 13 💬 |
984 | Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen | - | - | - | - | 1件: 299 299 💬 |
985 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
986 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
987 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
988 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
989 | Laquinimod capsules 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 2件: 8 8, 96 💬 |
990 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
991 | Laquinimod Cápsulas 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 96 96 💬 |
992 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
993 | LAU-7b | - | - | - | - | 1件: 299 299 💬 |
994 | LC51-0255 | - | - | - | - | 1件: 97 97 💬 |
995 | LDP-02 | - | - | - | - | 2件: 96 96, 97 💬 |
996 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
997 | Lentiviral vector containing ABCA4 gene | - | - | - | - | 1件: 301 301 💬 |
998 | Lentiviral vector containing MYO7A gene | - | - | - | - | 2件: 90 90, 303 💬 |
999 | Lentiviral vector containing the human MY07A gene | - | - | - | - | 2件: 90 90, 303 💬 |
1000 | Lentiviral Vector Trans-Skip gene modified Autologous Mesoangioblasts | - | - | - | - | 1件: 113 113 💬 |
1001 | Lentiviral vector transduced CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
1002 | Leuprorelin Acetate 3.75mg Injection | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1003 | Levodopa 75 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1004 | Levodopa-Carbidopa XL tablet (M) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1005 | Lidocaine 2% without vessel constrictor | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 51 51 💬 |
1006 | Liofen XL | - | - | - | - | 1件: 13 13 💬 |
1007 | LIQ861 75 µg | - | - | - | - | 1件: 86 86 💬 |
1008 | LIQ861 79.5 µg | - | - | - | - | 1件: 86 86 💬 |
1009 | LJN452, 0,01 mg | - | - | - | - | 1件: 93 93 💬 |
1010 | LJN452, 0,03 mg | - | - | - | - | 1件: 93 93 💬 |
1011 | LJN452, 0,1 mg | - | - | - | - | 1件: 93 93 💬 |
1012 | Lloprost(Ventavis,BAYQ6252, 10 µg/mL) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1013 | Lloprost(Ventavis,BAYQ6252, 20 µg/mL) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1014 | Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
1015 | Low dose vehicle control | - | - | - | - | 1件: 46 46 💬 |
1016 | Low Dose-VIS649 | - | - | - | - | 1件: 66 66 💬 |
1017 | LP-08 20mg | - | - | - | - | 1件: 226 226 💬 |
1018 | LP-08 80mg | - | - | - | - | 1件: 226 226 💬 |
1019 | LT-02 | - | - | - | - | 1件: 97 97 💬 |
1020 | LT-02 (modified-release PC pellets) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
1021 | LTS 0.25mg | - | - | - | - | 1件: 46 46 💬 |
1022 | LTS 0.5mg | - | - | - | - | 1件: 46 46 💬 |
1023 | LTS 1.0mg | - | - | - | - | 1件: 46 46 💬 |
1024 | Lu 00-800 | - | - | - | - | 1件: 6 6 💬 |
1025 | LU 70274 | - | - | - | - | 1件: 299 299 💬 |
1026 | Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1027 | Lym-X-Sorb powder | - | - | - | - | 1件: 299 299 💬 |
1028 | M2951 75 mg QD | - | - | - | - | 1件: 46 46 💬 |
1029 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1030 | Macitentan 75 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1031 | Marketed plasma-derived VWF/FVIII concentrate | - | - | - | - | 1件: 288 288 💬 |
1032 | Masitinib (3.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1033 | Masitinib (6.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1034 | Masitinib 6.0 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
1035 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1036 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1037 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
1038 | MD-0901 | - | - | - | - | 1件: 97 97 💬 |
1039 | MD-711 | - | - | - | - | 1件: 86 86 💬 |
1040 | MDGN-002 | - | - | - | - | 1件: 96 96 💬 |
1041 | Measles, Mumps, Rubella vaccination | - | - | - | - | 1件: 107 107 💬 |
1042 | MEDI-570 0.03 MG | - | - | - | - | 1件: 49 49 💬 |
1043 | MEDI-570 0.1 MG | - | - | - | - | 1件: 49 49 💬 |
1044 | MEDI-570 0.3 MG | - | - | - | - | 1件: 49 49 💬 |
1045 | Medical Air vs Oxygen | 2件: Medical air Medical air, Oxygen | 1件: Oxygen
Oxygen
💬 | - | - | 1件: 193 193 💬 |
1046 | Medium Dose-VIS649 | - | - | - | - | 1件: 66 66 💬 |
1047 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1048 | Meloxicam 0.125 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1049 | Meloxicam 0.25 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1050 | Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | - | - | - | - | 1件: 13 13 💬 |
1051 | MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC | 9件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Meningococcal polysaccharide vaccine group A, Meningococcal polysaccharide vaccine group C, Meningococcal polysaccharide vaccine group W-135, Meningococcal polysaccharide vaccine group Y, Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen | 2件: Meningococcal polysaccharide vaccine group A
Meningococcal polysaccharide vaccine group A
,
Meningococcal polysaccharide vaccine group C
💬 | - | - | 2件: 62 62, 66 💬 |
1052 | Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie | 1件: Meropenem Meropenem | 2件: Meropenem
Meropenem
,
Meropenem
💬 | - | - | 1件: 299 299 💬 |
1053 | Mesenchymal stem cell 0.5 | - | - | - | - | 1件: 228 228 💬 |
1054 | Mesenchymal stem cell 1.0 | - | - | - | - | 1件: 228 228 💬 |
1055 | Metex 7,5mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
1056 | Metformin XR | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
1057 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
1058 | Methotrexate plus ERB-041 for 12 weeks | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1059 | METHOTREXATE*7,5MG/ML 4SIR. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1060 | Methylprednisolone 1250 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1061 | METILPREDNISOLONE HIKMA - 1000 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONCINI IN VETRO | - | - | - | - | 1件: 300 300 💬 |
1062 | MetoHEXAL® Succ ® 23,75 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
1063 | Mezavant XL | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1064 | Mezavant XL 1200 mg gastro-resistant prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1065 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1066 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets. | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1067 | Mezavant XL 1200mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1068 | Mezavant XL Gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1069 | MH004 Ia(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1070 | MH004 Ia(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1071 | MH004 Ib-1(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1072 | MH004 Ib-1(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1073 | MH004 Ib-2(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1074 | Mid dose ANAVEX2-73 | - | - | - | - | 1件: 6 6 💬 |
1075 | Mirapexin extended release various strengths | 2件: Manganese citrate Manganese citrate, Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1076 | MIRAPEXIN*30CPR 0,7MG | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1077 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1078 | MK-0653 | - | - | - | - | 1件: 260 260 💬 |
1079 | MK-0663 | - | - | - | - | 2件: 46 46, 271 💬 |
1080 | MK-0859 | - | - | - | - | 1件: 79 79 💬 |
1081 | MK-0873 | 1件: MK-0873 MK-0873 | - | - | - | 1件: 46 46 💬 |
1082 | MK-7962 | - | - | - | - | 1件: 86 86 💬 |
1083 | MLN0002 (Vedolizumab) | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
1084 | MM-093 | 1件: MM-093 MM-093 | - | - | - | 1件: 46 46 💬 |
1085 | MN-001 | - | - | - | - | 1件: 226 226 💬 |
1086 | MN-001 BID | - | - | - | - | 1件: 226 226 💬 |
1087 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
1088 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
1089 | Moderna COVID-19 Vaccine | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 46 46 💬 |
1090 | MORAb-022 | - | - | - | - | 1件: 46 46 💬 |
1091 | MORF-057 | - | - | - | - | 1件: 97 97 💬 |
1092 | Most recent vaccine to seasonal influenza | - | - | - | - | 1件: 13 13 💬 |
1093 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
1094 | Mozobil 20mg/mL vial (injectable solution for subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
1095 | Mozobil 20mg/mL vial (injectable solution, subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
1096 | MR-MC-01 | - | - | - | - | 1件: 226 226 💬 |
1097 | MRA 003 US | - | - | - | - | 1件: 49 49 💬 |
1098 | MRNA COVD19 vaccine | - | - | - | - | 3件: 49 49, 53, 271 💬 |
1099 | MSC injection 01 | - | - | - | - | 1件: 96 96 💬 |
1100 | MSC injection 02 | - | - | - | - | 1件: 96 96 💬 |
1101 | MSC treatment 01 | - | - | - | - | 1件: 96 96 💬 |
1102 | MSC treatment 02 | - | - | - | - | 1件: 96 96 💬 |
1103 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 💬 |
1104 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 💬 |
1105 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 💬 |
1106 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 💬 |
1107 | MT-7117 | - | - | - | - | 2件: 51 51, 254 💬 |
1108 | MT-7117 High Dose | - | - | - | - | 1件: 254 254 💬 |
1109 | MT-7117 Low Dose | - | - | - | - | 1件: 254 254 💬 |
1110 | MTC TRx0014-001 capsules | - | - | - | - | 1件: 127 127 💬 |
1111 | Multi-modal pain management [Valium + Gabapentin] | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
1112 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
1113 | MYO-029 | 1件: Stamulumab Stamulumab | 1件: Stamulumab
Stamulumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
1114 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1115 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1116 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1117 | N-0923 | - | - | - | - | 1件: 6 6 💬 |
1118 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
1119 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 💬 |
1120 | NaCl 0.9% | - | - | - | - | 1件: 39 39 💬 |
1121 | Nanobody directed towards the human A1 domain of von Willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 💬 |
1122 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
1123 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 288 288 💬 |
1124 | NBI-74788 | - | - | - | - | 1件: 81 81 💬 |
1125 | NBI-77860 | - | - | - | - | 1件: 81 81 💬 |
1126 | NBTX-001 | - | - | - | - | 1件: 6 6 💬 |
1127 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 💬 |
1128 | NEB/01-07 | - | - | - | - | 1件: 299 299 💬 |
1129 | Needle biopsy of the vastus lateralis muscle | - | - | - | - | 1件: 113 113 💬 |
1130 | NEUPRO*7CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1131 | NEUPRO*7CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1132 | NEUPRO*7CER 8MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1133 | NI-0101 | - | - | - | - | 1件: 46 46 💬 |
1134 | NI-03 | - | - | - | - | 1件: 298 298 💬 |
1135 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 💬 |
1136 | NI-0501 | - | - | - | - | 1件: 107 107 💬 |
1137 | NI-071 | - | - | - | - | 1件: 46 46 💬 |
1138 | NI-0801 | - | - | - | - | 1件: 93 93 💬 |
1139 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
1140 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1141 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 💬 |
1142 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 💬 |
1143 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 💬 |
1144 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 💬 |
1145 | NNC 126-0083 | - | - | - | - | 1件: 78 78 💬 |
1146 | NNC 142-0002 | - | - | - | - | 1件: 46 46 💬 |
1147 | NNC0109-0012 | - | - | - | - | 1件: 46 46 💬 |
1148 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 💬 |
1149 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 💬 |
1150 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 💬 |
1151 | NNC0142-0002 | - | - | - | - | 1件: 46 46 💬 |
1152 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 💬 |
1153 | NNC0195-0092 | - | - | - | - | 1件: 78 78 💬 |
1154 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1155 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 💬 |
1156 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1157 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
1158 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1159 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1160 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 💬 |
1161 | NNC109-0012 | - | - | - | - | 1件: 46 46 💬 |
1162 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 💬 |
1163 | NNC142-0002 | - | - | - | - | 1件: 96 96 💬 |
1164 | NNC151-0000 | - | - | - | - | 1件: 46 46 💬 |
1165 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 💬 |
1166 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 💬 |
1167 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 💬 |
1168 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1169 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 💬 |
1170 | NPC-02 | - | - | - | - | 1件: 171 171 💬 |
1171 | NPC-09 | - | - | - | - | 1件: 30 30 💬 |
1172 | NPI-001 | - | - | - | - | 2件: 90 90, 303 💬 |
1173 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
1174 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
1175 | NT-KO-003 | - | - | - | - | 1件: 13 13 💬 |
1176 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 💬 |
1177 | Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi | 4件: Epoprostenol Epoprostenol, Iloprost, Macitentan, Selexipag | 4件: Epoprostenol
Epoprostenol
,
Iloprost
,
Selexipag
,
Macitentan
💬 | 3件: EDNRA EDNRA, EDNRB, PTGIR 💬 | 10件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1178 | OCA (INT-747) | - | - | - | - | 1件: 93 93 💬 |
1179 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 💬 |
1180 | OCA 0.1mg | - | - | - | - | 1件: 296 296 💬 |
1181 | OCA, INT-747 | - | - | - | - | 1件: 93 93 💬 |
1182 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
1183 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1184 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1185 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1186 | Ofatumumab 700 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1187 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1188 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1189 | Omalizumab (Xolair) | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 65 65 💬 |
1190 | Omega-3 and Vitamin E supplementation | 2件: Omega-3 fatty acids Omega-3 fatty acids, Vitamin E | 1件: Vitamin E
Vitamin E
💬 | - | - | 1件: 46 46 💬 |
1191 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
1192 | Onasemnogene Abeparvovec-xioi | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
1193 | Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | 2件: Iodide Iodide, Sodium iodide | 3件: Sodium iodide
Sodium iodide
,
Sodium iodide I 123
,
Sodium iodide I 125
💬 | - | - | 1件: 34 34 💬 |
1194 | Oncoxin + Viusid | - | - | - | - | 1件: 46 46 💬 |
1195 | Open Label Topical Beremagene Geperpavec (B-VEC) | - | - | - | - | 1件: 36 36 💬 |
1196 | Optivate® (Human Coagulation Factor VIII) | 2件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1197 | Oral Glucose Tolerance test (75g 2-hour) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 💬 |
1198 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1199 | Oral Vancomycin | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 2件: 94 94, 296 💬 |
1200 | Oral Viscous Budesonide | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1201 | Oral Viscous Budesonide (OVB) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1202 | Ornithine transcarbamylase vector | 1件: Ornithine Ornithine | 1件: Ornithine
Ornithine
💬 | - | - | 1件: 251 251 💬 |
1203 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
1204 | Ortho-Novum 777 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
1205 | Ossium vBM-MSC | - | - | - | - | 1件: 96 96 💬 |
1206 | OSSM-001 | - | - | - | - | 1件: 96 96 💬 |
1207 | Other vasodilator | - | - | - | - | 1件: 51 51 💬 |
1208 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 💬 |
1209 | Over-encapsulated 75 mg Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1210 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1211 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1212 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1213 | P38 Inhibitor (4) 75mg | - | - | - | - | 1件: 46 46 💬 |
1214 | Panzytrat 25.000 | - | - | - | - | 1件: 298 298 💬 |
1215 | Panzytrat 25.000 FIP-E units of Lipase | - | - | - | - | 1件: 298 298 💬 |
1216 | Panzytrat® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1217 | Part 1, JM-010 component Group A | - | - | - | - | 1件: 6 6 💬 |
1218 | Part 1, JM-010 component Group B | - | - | - | - | 1件: 6 6 💬 |
1219 | Part 1, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
1220 | Part 2, JM-010 combination Group A | - | - | - | - | 1件: 6 6 💬 |
1221 | Part 2, JM-010 combination Group B | - | - | - | - | 1件: 6 6 💬 |
1222 | Part 2, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
1223 | Pasireotide 0.3mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1224 | Pasireotide 0.6 MG/ML | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1225 | Pasireotide 0.6mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1226 | Pasireotide 0.9 mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1227 | PAT-001, 0.1% | - | - | - | - | 1件: 160 160 💬 |
1228 | PAT-001, 0.2% | - | - | - | - | 1件: 160 160 💬 |
1229 | PB1046, VIP-ELP1-120, Vasomera | - | - | - | - | 1件: 86 86 💬 |
1230 | PCCLchimGp91s lentiviral vector transduced CD34+ cells infusion | - | - | - | - | 1件: 65 65 💬 |
1231 | PD 0299685 | - | - | - | - | 1件: 226 226 💬 |
1232 | PD 0299685 at 15mg BID | - | - | - | - | 1件: 226 226 💬 |
1233 | PD 0299685 at 30mg BID | - | - | - | - | 1件: 226 226 💬 |
1234 | PD 0360324 | - | - | - | - | 2件: 46 46, 84 💬 |
1235 | PD vitamin supplementation | - | - | - | - | 1件: 6 6 💬 |
1236 | PD-0299685 | 1件: PD-0299685 PD-0299685 | - | - | - | 1件: 226 226 💬 |
1237 | PD-0325901 | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1238 | Pertussis vaccine | 1件: Pertussis vaccine Pertussis vaccine | 1件: Pertussis vaccine
Pertussis vaccine
💬 | - | - | 2件: 13 13, 46 💬 |
1239 | PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714 | - | - | - | - | 1件: 85 85 💬 |
1240 | PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
1241 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 💬 |
1242 | PF-00547659 | - | - | - | - | 2件: 96 96, 97 💬 |
1243 | PF-00547659 SC injection | - | - | - | - | 2件: 96 96, 97 💬 |
1244 | PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
1245 | PF-04171327 | - | - | - | - | 1件: 46 46 💬 |
1246 | PF-04171327 10 mg | - | - | - | - | 1件: 46 46 💬 |
1247 | PF-04171327 25 mg | - | - | - | - | 1件: 46 46 💬 |
1248 | PF-04236921 | - | - | - | - | 2件: 49 49, 96 💬 |
1249 | PF-04236921 SC injection | - | - | - | - | 1件: 96 96 💬 |
1250 | PF-04383119 | - | - | - | - | 1件: 226 226 💬 |
1251 | PF-05208763 | - | - | - | - | 1件: 67 67 💬 |
1252 | PF-05230917 | - | - | - | - | 1件: 97 97 💬 |
1253 | PF-05280586 | - | - | - | - | 1件: 46 46 💬 |
1254 | PF-05285401 | - | - | - | - | 1件: 97 97 💬 |
1255 | PF-06252616 | 1件: Domagrozumab Domagrozumab | 1件: Domagrozumab
Domagrozumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
1256 | PF-06291826-83/Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
1257 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 💬 |
1258 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 💬 |
1259 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 💬 |
1260 | PF-06410293 | - | - | - | - | 1件: 46 46 💬 |
1261 | PF-06412562 | - | - | - | - | 1件: 6 6 💬 |
1262 | PF-06438179 | - | - | - | - | 1件: 46 46 💬 |
1263 | PF-06462700 | - | - | - | - | 1件: 60 60 💬 |
1264 | PF-06480605 | - | - | - | - | 1件: 97 97 💬 |
1265 | PF-06480605 100 mg/ml | - | - | - | - | 1件: 97 97 💬 |
1266 | PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1267 | PF-06649751 - 15mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1268 | PF-06649751 - 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1269 | PF-06649751 - 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1270 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1271 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1272 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1273 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1274 | PF-06650833 | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
1275 | PF-06650833 100 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
1276 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
1277 | PF-06651600 | 1件: PF-06651600 PF-06651600 | - | - | - | 3件: 46 46, 96, 97 💬 |
1278 | PF-06651600 10 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 97 97 💬 |
1279 | PF-06651600 50 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
1280 | PF-06651600 50mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 96 96 💬 |
1281 | PF-06651600-15 | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
1282 | PF-06669571 | - | - | - | - | 1件: 6 6 💬 |
1283 | PF-06687234 | - | - | - | - | 1件: 97 97 💬 |
1284 | PF-06700841 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
1285 | PF-06700841 15 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
1286 | PF-06700841 25 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 2件: 96 96, 97 💬 |
1287 | PF-06700841 25mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
1288 | PF-06700841 30 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
1289 | PF-06700841 45 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
1290 | PF-06700841 5 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
1291 | PF-06700841 5mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
1292 | PF-06700841-15 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
1293 | PF-06730512 | - | - | - | - | 1件: 222 222 💬 |
1294 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 💬 |
1295 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 💬 |
1296 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 💬 |
1297 | PF-06823859 | - | - | - | - | 1件: 50 50 💬 |
1298 | PF-06823859 high | - | - | - | - | 1件: 50 50 💬 |
1299 | PF-06823859 low | - | - | - | - | 1件: 50 50 💬 |
1300 | PF-06826647 | - | - | - | - | 1件: 97 97 💬 |
1301 | PF-06826647 100 mg QD | - | - | - | - | 1件: 97 97 💬 |
1302 | PF-06826647 300 mg QD | - | - | - | - | 1件: 97 97 💬 |
1303 | PF-06826647 600 mg QD | - | - | - | - | 1件: 97 97 💬 |
1304 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 💬 |
1305 | PF-06836922 | - | - | - | - | 1件: 78 78 💬 |
1306 | PF-06939926 | - | - | - | - | 1件: 113 113 💬 |
1307 | PF-07054894 | - | - | - | - | 1件: 97 97 💬 |
1308 | PF-07256472 | - | - | - | - | 1件: 276 276 💬 |
1309 | PG-760564 | - | - | - | - | 1件: 46 46 💬 |
1310 | PH-797804 | 1件: PH-797804 PH-797804 | - | - | - | 1件: 46 46 💬 |
1311 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
1312 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
1313 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
1314 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
1315 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
1316 | PHA-794,428 | - | - | - | - | 1件: 78 78 💬 |
1317 | PHA-794428 | - | - | - | - | 1件: 78 78 💬 |
1318 | Phenylalanine-free protein substitute in tablet form (XPhe minis) | 1件: Phenylalanine Phenylalanine | 1件: Phenylalanine
Phenylalanine
💬 | - | - | 1件: 240 240 💬 |
1319 | Phylloquinone (vitamin K1) | 1件: Phylloquinone Phylloquinone | - | - | - | 1件: 96 96 💬 |
1320 | PI-0824 | 1件: PI-0824 PI-0824 | - | - | - | 1件: 35 35 💬 |
1321 | Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
1322 | Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
1323 | PIR, S-7701 | - | - | - | - | 1件: 85 85 💬 |
1324 | Pirepemat x fumarate | - | - | - | - | 1件: 6 6 💬 |
1325 | PL 00095/5079R | - | - | - | - | 1件: 46 46 💬 |
1326 | PL 0010/0211 | - | - | - | - | 1件: 299 299 💬 |
1327 | PL 00512/0150 | - | - | - | - | 1件: 298 298 💬 |
1328 | PL 04515/0127 | - | - | - | - | 1件: 13 13 💬 |
1329 | PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 57 57 💬 |
1330 | PL 12762/0049 | - | - | - | - | 1件: 13 13 💬 |
1331 | PL 17901/0122 | - | - | - | - | 1件: 96 96 💬 |
1332 | PL 20532/0012 | - | - | - | - | 1件: 96 96 💬 |
1333 | Plasma-derived FVIII/VWF concentrate | - | - | - | - | 1件: 288 288 💬 |
1334 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1335 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
1336 | PLN-74809 | 1件: PLN-74809 PLN-74809 | - | - | - | 2件: 85 85, 94 💬 |
1337 | PLN-74809-000 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
1338 | PLN-74809-020 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
1339 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
1340 | PMG1015 Dose 7 | - | - | - | - | 1件: 85 85 💬 |
1341 | Pneumococcal conjugate vaccine | - | - | - | - | 1件: 46 46 💬 |
1342 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) | - | - | - | - | 2件: 13 13, 14 💬 |
1343 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE | 4件: Aluminium Aluminium, Aluminium phosphate, Corynebacterium diphtheriae CRM197 protein, Phosphate ion | - | - | - | 1件: 46 46 💬 |
1344 | Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | - | - | - | - | 1件: 46 46 💬 |
1345 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | - | - | - | - | 1件: 46 46 💬 |
1346 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F | - | - | - | - | 1件: 222 222 💬 |
1347 | Pneumococcal polysaccharide vaccine | - | - | - | - | 3件: 13 13, 46, 222 💬 |
1348 | PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT) | - | - | - | - | 1件: 46 46 💬 |
1349 | Pneumococcal polysaccharide vaccine 23 valent | - | - | - | - | 1件: 265 265 💬 |
1350 | Pneumococcal polysaccharide vaccine solution for injection in a vial | - | - | - | - | 1件: 222 222 💬 |
1351 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
1352 | Pneumovax® (pneumococcal polysaccharide vaccine) | - | - | - | - | 1件: 65 65 💬 |
1353 | PR-06410293 | - | - | - | - | 1件: 46 46 💬 |
1354 | Pramipexole 0.125 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1355 | Pramipexole 0.5 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1356 | Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1357 | Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1358 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1359 | Prednisone 7.5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1360 | Pregabalin 75mg | 1件: Pregabalin Pregabalin | 1件: Pregabalin
Pregabalin
💬 | 4件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 💬 | 7件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway 💬 | 1件: 70 70 💬 |
1361 | PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
1362 | Prevenar vaccination | - | - | - | - | 1件: 46 46 💬 |
1363 | Prevenar vaccine | - | - | - | - | 1件: 46 46 💬 |
1364 | Prevenar® (7-valent pneumococcal conjugate vaccine) | - | - | - | - | 1件: 65 65 💬 |
1365 | PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML | - | - | - | - | 1件: 51 51 💬 |
1366 | PRO045, 0.15 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1367 | PRO045, 1.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1368 | PRO045, 3.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1369 | PRO045, 6.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1370 | PRO045, 9.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1371 | Probiotic - VSL#3 | - | - | - | - | 1件: 96 96 💬 |
1372 | Probiotics (Visbiome®) | - | - | - | - | 1件: 13 13 💬 |
1373 | Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal) | - | - | - | - | 1件: 13 13 💬 |
1374 | Prototype capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1375 | PRTX-100 at 12.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
1376 | PRTX-100 at 3.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
1377 | PRTX-100 at 6.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
1378 | PSRS11.EFS.IL2RG.pre* retroviral vector | - | - | - | - | 1件: 65 65 💬 |
1379 | PSRS11.EFS.IL2RG.pre* retroviral vector transduce | - | - | - | - | 1件: 65 65 💬 |
1380 | PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells | - | - | - | - | 1件: 65 65 💬 |
1381 | PT320 2.0 mg | - | - | - | - | 1件: 6 6 💬 |
1382 | PTC-0161480 | - | - | - | - | 2件: 246 246, 299 💬 |
1383 | PTR-01 | - | - | - | - | 1件: 36 36 💬 |
1384 | PTW-002 10 mg/g gel | - | - | - | - | 1件: 36 36 💬 |
1385 | PUR 0110 | - | - | - | - | 1件: 97 97 💬 |
1386 | PUR 0110 Rectal Enema | - | - | - | - | 1件: 97 97 💬 |
1387 | PUR 0110 Rectal Enema 1000 mg | - | - | - | - | 1件: 97 97 💬 |
1388 | PUR 0110 Rectal Enema 250 mg | - | - | - | - | 1件: 97 97 💬 |
1389 | PUR 0110 Rectal Enema 500 mg | - | - | - | - | 1件: 97 97 💬 |
1390 | Purified Vero Cell Vaccine) | - | - | - | - | 1件: 65 65 💬 |
1391 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 💬 |
1392 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 💬 |
1393 | Qing Re Huo Xue (QRHX) | - | - | - | - | 1件: 46 46 💬 |
1394 | QLS-101 ophthalmic solution, 2.0 % | - | - | - | - | 1件: 157 157 💬 |
1395 | QR-010 | - | - | - | - | 1件: 299 299 💬 |
1396 | QRL-201 - Dose 7 | - | - | - | - | 1件: 2 2 💬 |
1397 | QTXEW2-04-AF, EW2, GC-1, QRX-431 | - | - | - | - | 1件: 20 20 💬 |
1398 | Quadrivalent HPV vaccine | - | - | - | - | 1件: 107 107 💬 |
1399 | Quadrivalent influenza vaccine | - | - | - | - | 1件: 13 13 💬 |
1400 | R-021 | - | - | - | - | 1件: 222 222 💬 |
1401 | R788 sodium hexahydrate, RIG2-01, RIG-G | - | - | - | - | 1件: 46 46 💬 |
1402 | RAAV.hPDE6A vector | - | - | - | - | 1件: 90 90 💬 |
1403 | RAAV2-CB-hAAT Gene Vector | - | - | - | - | 1件: 231 231 💬 |
1404 | RAAV2/2-ND4 VECTOR | - | - | - | - | 1件: 302 302 💬 |
1405 | RAAV2/5-PBGD vector dosage 1 | - | - | - | - | 1件: 254 254 💬 |
1406 | RAAV2/5-PBGD vector dosage 2 | - | - | - | - | 1件: 254 254 💬 |
1407 | RAAV2/5-PBGD vector dosage 3 | - | - | - | - | 1件: 254 254 💬 |
1408 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 💬 |
1409 | RAAV2/6 Left ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
1410 | RAAV2/6 Right ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
1411 | RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
1412 | RANEXA*60CPR 750MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
1413 | Ranibizumab injection (0.5 mg) | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 2件: 166 166, 301 💬 |
1414 | Ranolazine 750 mg PR tablets | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
1415 | Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
1416 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
1417 | Rasagiline mesylate 1.0 mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1418 | RAvPAL-PEG 0.001 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
1419 | RAvPAL-PEG 0.003 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
1420 | RAvPAL-PEG 0.01 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
1421 | RAvPAL-PEG 0.03 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
1422 | RAvPAL-PEG 0.1 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
1423 | RE-021 | - | - | - | - | 3件: 66 66, 218, 222 💬 |
1424 | RE-021 (Sparsentan) | 1件: Sparsentan Sparsentan | 1件: Sparsentan
Sparsentan
💬 | 2件: AGTR1 AGTR1, EDNRA 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1425 | RE-024 | - | - | - | - | 1件: 120 120 💬 |
1426 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1427 | Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1428 | Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 gene | - | - | - | - | 1件: 302 302 💬 |
1429 | Recombinant AAV vector serotype 2 containing the human wild typemitochondrial ND4 gene | - | - | - | - | 1件: 302 302 💬 |
1430 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR EXPRESSING THE HUMAN ALPHA-1-ANTITRYPSIN GENE | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
1431 | Recombinant adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene | - | - | - | - | 1件: 90 90 💬 |
1432 | Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4) | 1件: NADH NADH | - | - | - | 1件: 302 302 💬 |
1433 | Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galactosidase A | - | - | - | - | 1件: 19 19 💬 |
1434 | Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase | 1件: Alglucosidase alfa Alglucosidase alfa | 1件: Alglucosidase alfa
Alglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
1435 | Recombinant coagulation FVIII Fc – von Willebrand factor – XTEN fusion protein | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1436 | Recombinant coagulation FVIII Fc –von Willebrand factor – XTEN fusion protein | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1437 | Recombinant factor VIIII (rFVIII) | - | - | - | - | 1件: 288 288 💬 |
1438 | Recombinant Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
1439 | Recombinant Factor XIII (rFXIII) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 2件: 97 97, 288 💬 |
1440 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTO | 2件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1441 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR - | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1442 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR - XTEN FUSION PROTEIN | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1443 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR -XTEN FUSION PROTEIN | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1444 | Recombinant human interleukin-7 | 1件: Interleukin-7 Interleukin-7 | - | - | - | 1件: 25 25 💬 |
1445 | Recombinant human von Willebrand Factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1446 | Recombinant porcine coagulation factor VIII (B domain deleted) | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1447 | Recombinant porcine coagulation factor VIII (B-domain deleted) | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1448 | Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene | - | - | - | - | 1件: 19 19 💬 |
1449 | Recombinant von Willebrand Factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1450 | Recombinant von Willebrand Factor (rVWF) | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1451 | Recombinant von Willebrand Factor 1300IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1452 | Recombinant von Willebrand Factor 650IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1453 | Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII) | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1454 | Recombinant zoster vaccine | - | - | - | - | 2件: 13 13, 49 💬 |
1455 | Recomibnant human Von Willebrand Factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1456 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
1457 | Reference capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1458 | REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1459 | Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1460 | REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
1461 | REQUIP 21 CPR 0,25 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1462 | REQUIP 21 CPR 0,5 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1463 | Requip XL prolonged-release | 2件: Manganese citrate Manganese citrate, Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1464 | REQUIP*21CPR 0,25MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1465 | REQUIP*21CPR 0,5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1466 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
1467 | Revatio 0.8mg/ml solution for injection | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
1468 | Revolade 75 mg | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
1469 | RFB002, rhuFab V2 | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 166 166 💬 |
1470 | RG-012 | - | - | - | - | 1件: 218 218 💬 |
1471 | RGB-03 | - | - | - | - | 1件: 46 46 💬 |
1472 | RGH-706 | - | - | - | - | 1件: 193 193 💬 |
1473 | RhuDex 25 mg (31.75 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
1474 | RhuFab V2 | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 166 166 💬 |
1475 | RhuMAb Beta7, Anti Beta 7, PRO145223 | - | - | - | - | 1件: 97 97 💬 |
1476 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
1477 | Rifaximin 550 MG Oral Tablet [XIFAXAN] | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 299 299 💬 |
1478 | Riociguat coated tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1479 | Riociguat coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1480 | Riociguat coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1481 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1482 | Rituximab-EU+ Rituximab-Pfizer x 2 Courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1483 | Rituximab-Pfizer (PF-05280586) x 3 courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1484 | Rituximab-US + Rituximab-Pfizer x 2 Courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1485 | RNL-Vascostem® | - | - | - | - | 1件: 47 47 💬 |
1486 | Ro 001-9265 | - | - | - | - | 1件: 41 41 💬 |
1487 | Ro 001-9265/F02 | - | - | - | - | 1件: 41 41 💬 |
1488 | RO 001-9265/F02-01 | - | - | - | - | 1件: 46 46 💬 |
1489 | Ro 001-9265/F03 | - | - | - | - | 1件: 41 41 💬 |
1490 | Ro 001-9265/F04 | - | - | - | - | 1件: 41 41 💬 |
1491 | Ro 002-9893/F02 | - | - | - | - | 1件: 46 46 💬 |
1492 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 💬 |
1493 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
1494 | Ro 48-77533 | - | - | - | - | 1件: 46 46 💬 |
1495 | RO 487-7533 | - | - | - | - | 1件: 46 46 💬 |
1496 | Ro 487-7533/F01 | - | - | - | - | 3件: 46 46, 107, 271 💬 |
1497 | Ro 487-7533/F10 | - | - | - | - | 2件: 46 46, 107 💬 |
1498 | Ro 487-7533/F10-02 | - | - | - | - | 1件: 46 46 💬 |
1499 | Ro 487-7533/F10-04 | - | - | - | - | 4件: 41 41, 46, 51, 107 💬 |
1500 | Ro 491-7523/F18 | - | - | - | - | 1件: 206 206 💬 |
1501 | Ro 491-7523/F19 | - | - | - | - | 1件: 206 206 💬 |
1502 | Ro 533-3787/F01- 06 | - | - | - | - | 1件: 13 13 💬 |
1503 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 💬 |
1504 | Ro 549-0261/F04 | - | - | - | - | 1件: 97 97 💬 |
1505 | Ro 549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
1506 | Ro 549-0261/F08-02 | - | - | - | - | 1件: 96 96 💬 |
1507 | Ro 723-4292/F02 | - | - | - | - | 1件: 8 8 💬 |
1508 | Ro-47-0203 | - | - | - | - | 1件: 86 86 💬 |
1509 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 💬 |
1510 | RO0452294/V01 | - | - | - | - | 2件: 43 43, 44 💬 |
1511 | RO0452294/V02 | - | - | - | - | 3件: 35 35, 43, 44 💬 |
1512 | RO452294/V02 | - | - | - | - | 1件: 46 46 💬 |
1513 | Ro47-0203 | - | - | - | - | 1件: 86 86 💬 |
1514 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
1515 | Ro487-7533 | - | - | - | - | 1件: 46 46 💬 |
1516 | RO487-7533/F01-F05 | - | - | - | - | 1件: 46 46 💬 |
1517 | RO487-7533/F10-04 | - | - | - | - | 2件: 46 46, 51 💬 |
1518 | RO4917523 0.5 mg | - | - | - | - | 1件: 206 206 💬 |
1519 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 💬 |
1520 | Ro549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
1521 | RO5490255/F01-02 | - | - | - | - | 1件: 85 85 💬 |
1522 | RO5490261/F04-02 | - | - | - | - | 1件: 97 97 💬 |
1523 | RO7112689/F03-01 | - | - | - | - | 2件: 62 62, 109 💬 |
1524 | RO7123520/F03-01 | - | - | - | - | 1件: 46 46 💬 |
1525 | RO7204239/F01-01 | - | - | - | - | 1件: 3 3 💬 |
1526 | RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1527 | RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1528 | RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
1529 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
1530 | RO7490677/ F01-02 | - | - | - | - | 1件: 85 85 💬 |
1531 | RO7490677/F01-01 | - | - | - | - | 1件: 85 85 💬 |
1532 | RO7490677/F01-02 | - | - | - | - | 1件: 85 85 💬 |
1533 | RO7490677/F01-03 | - | - | - | - | 1件: 85 85 💬 |
1534 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
1535 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1536 | Ropinirole PR/XR | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1537 | Ropinirole PR/XR Tablets | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1538 | Ropinirole prolonged release/extended release(PR/XR) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1539 | Ropinirole XL | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1540 | Ropinirole XL (formerly CR) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1541 | Rosiglitazone XR | 1件: Rosiglitazone Rosiglitazone | 1件: Rosiglitazone
Rosiglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 46 46 💬 |
1542 | RQ-00000010 | - | - | - | - | 1件: 6 6 💬 |
1543 | RST-001 | - | - | - | - | 1件: 90 90 💬 |
1544 | RT234 - vardenafil inhalation powder | 1件: Vardenafil Vardenafil | 1件: Vardenafil
Vardenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1545 | RVG 03820 | - | - | - | - | 1件: 3 3 💬 |
1546 | RVG 05565 | - | - | - | - | 1件: 96 96 💬 |
1547 | RVG 07151 | - | - | - | - | 1件: 96 96 💬 |
1548 | RVG 08740 | - | - | - | - | 1件: 6 6 💬 |
1549 | RVG 08938 | - | - | - | - | 1件: 75 75 💬 |
1550 | RWJ-445380-002 | - | - | - | - | 1件: 46 46 💬 |
1551 | SA-001 | - | - | - | - | 1件: 298 298 💬 |
1552 | SACUBITRIL VALSARTAN | 2件: Sacubitril Sacubitril, Valsartan | 2件: Valsartan
Valsartan
,
Sacubitril
💬 | 2件: AGTR1 AGTR1, MME 💬 | 19件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hematopoietic cell lineage, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Protein digestion and absorption, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1553 | Sacubitril/Valsartan | 2件: Sacubitril Sacubitril, Valsartan | 2件: Valsartan
Valsartan
,
Sacubitril
💬 | 2件: AGTR1 AGTR1, MME 💬 | 19件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hematopoietic cell lineage, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Protein digestion and absorption, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1554 | SAGE-718 | - | - | - | - | 2件: 6 6, 8 💬 |
1555 | Saline 0.9% inhalation solution | - | - | - | - | 1件: 299 299 💬 |
1556 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
1557 | SAMSCA 7.5 mg oral tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1558 | SAN-300 0.5 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
1559 | SAN-300 1.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
1560 | SAN-300 2.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
1561 | SAN-300 4.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
1562 | SAN-300 4.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
1563 | SARS-COV-2 mRNA Vaccine | 2件: CVnCoV CVnCoV, SARS-CoV-2 mRNA vaccine | - | - | - | 1件: 13 13 💬 |
1564 | Sativex 2,7mg/2,5 mg Solucion para pulverizacion bucal | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
1565 | Satralizumab (120 mg/vial) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
1566 | Satralizumab (120mg/vial) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
1567 | SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
1568 | SBI-087 | - | - | - | - | 2件: 46 46, 49 💬 |
1569 | SBT-020 | - | - | - | - | 1件: 8 8 💬 |
1570 | SCM-010 | - | - | - | - | 1件: 13 13 💬 |
1571 | SCYX-7158 | - | - | - | - | 1件: 65 65 💬 |
1572 | SD-101-6.0 cream | - | - | - | - | 1件: 36 36 💬 |
1573 | Search for exocrine pancreatic insufficiency at week 0 and 12 | - | - | - | - | 1件: 96 96 💬 |
1574 | Seasonal influenza vaccine | - | - | - | - | 2件: 13 13, 46 💬 |
1575 | Seasonal influenza vaccine available for the 2012-2013 vaccine campaign | - | - | - | - | 1件: 84 84 💬 |
1576 | Seasonal Quadrivalent influenza vaccine | - | - | - | - | 1件: 13 13 💬 |
1577 | Sebelipase alfa 0.35 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
1578 | Secukinumab (75 mg) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
1579 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
1580 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
1581 | Selumetinib granules in sprinkle capsules for opening 7.5 mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1582 | Semi-vegetarian diet | - | - | - | - | 1件: 97 97 💬 |
1583 | Serum physiologique 0.9 % | - | - | - | - | 1件: 96 96 💬 |
1584 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
1585 | SGT-001 | - | - | - | - | 1件: 113 113 💬 |
1586 | SI-722 | - | - | - | - | 1件: 226 226 💬 |
1587 | Sifrol 0,088 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1588 | Sifrol 0,18 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1589 | Sifrol 0,35 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1590 | Sifrol 0,7 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1591 | Sifrol, 0,35 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1592 | Sifrol, 0,70 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1593 | SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1594 | SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1 | - | - | - | - | 1件: 36 36 💬 |
1595 | Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre | - | - | - | - | 1件: 65 65 💬 |
1596 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1597 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
1598 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
1599 | Sirolimus 0,1% crème | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
1600 | Sirolimus 0.2% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
1601 | Sirolimus 0.4% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
1602 | SKI-O-703 | - | - | - | - | 1件: 46 46 💬 |
1603 | SKI-O-703 capsule | - | - | - | - | 1件: 46 46 💬 |
1604 | SLS-005 | - | - | - | - | 1件: 2 2 💬 |
1605 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 💬 |
1606 | Sodio valproato | - | - | - | - | 1件: 144 144 💬 |
1607 | Sodium chloride (7%) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1608 | Sodium chloride 0,9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1609 | Sodium Chloride 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 2件: 14 14, 227 💬 |
1610 | SODIUM CHLORIDE 7% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1611 | SODIUM CHLORIDE SOLUTION 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 51 51, 60, 288, 299 💬 |
1612 | Sodium Pyruvate in 0.9% Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1613 | Sodium Valproate | 1件: Valproic acid Valproic acid | 1件: Valproic acid
Valproic acid
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 4件: 2 2, 90, 102, 256 💬 |
1614 | Sodium valproate 200 mg gastro-resistant tablets | 1件: Valproic acid Valproic acid | 1件: Valproic acid
Valproic acid
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 233 233 💬 |
1615 | Sodium Valproate 200Mg E/C Tablet | 1件: Valproic acid Valproic acid | 1件: Valproic acid
Valproic acid
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 233 233 💬 |
1616 | Sodium Valproate Wockhardt 200mg Gastro-Resistant tablets | 1件: Valproic acid Valproic acid | 1件: Valproic acid
Valproic acid
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 233 233 💬 |
1617 | Solifenacin Succinate (VESIcare) | 1件: Solifenacin Solifenacin | 1件: Solifenacin
Solifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 6 6 💬 |
1618 | SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML) | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 13 13, 62, 109 💬 |
1619 | Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone cypionate, Hydrocortisone succinate | 3件: Hydrocortisone
Hydrocortisone
,
Hydrocortisone cypionate
,
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
1620 | Soluble Ve cadherin | - | - | - | - | 1件: 51 51 💬 |
1621 | Somatic gene-therapy by X-CGD | - | - | - | - | 1件: 65 65 💬 |
1622 | Somatropin - GH naïve pediatric cohort | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
1623 | Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate | 5件: Arginine Arginine, Clonidine, Estradiol, Estradiol valerate, Somatotropin | 4件: Estradiol
Estradiol
,
Clonidine
,
Estradiol valerate
,
Arginine
💬 | 5件: ADRA2A ADRA2A, ADRA2B, ADRA2C, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Neuroactive ligand-receptor interaction, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
1624 | Somavaratan (VRS-317) | 1件: Somavaratan Somavaratan | 1件: Somavaratan
Somavaratan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
1625 | Sotatercept - 45 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
1626 | Sotatercept - 60 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
1627 | SPI-1005 Ebselen 200mg Capsule x1 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
1628 | SPI-1005 Ebselen 200mg Capsule x2 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
1629 | SPI-1005 Ebselen 200mg Capsule x3 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
1630 | SPP-004 | - | - | - | - | 1件: 21 21 💬 |
1631 | SRK-015 | - | - | - | - | 1件: 3 3 💬 |
1632 | SSP-004184 100 mg | - | - | - | - | 1件: 284 284 💬 |
1633 | SSP-004184 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1634 | SSP-004184 250 mg | - | - | - | - | 1件: 284 284 💬 |
1635 | SSP-004184 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1636 | SSP-004184 375 mg | - | - | - | - | 1件: 284 284 💬 |
1637 | SSP-004184 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1638 | SSP-004184 50 mg | - | - | - | - | 1件: 284 284 💬 |
1639 | SSP-004184 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1640 | SSP-004184 500 mg | - | - | - | - | 1件: 284 284 💬 |
1641 | SSP-004184 500 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1642 | SSP-004184AQ 100 mg | - | - | - | - | 1件: 284 284 💬 |
1643 | SSP-004184AQ 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1644 | SSP-004184AQ 200 mg | - | - | - | - | 1件: 284 284 💬 |
1645 | SSP-004184AQ 200 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1646 | SSP-004184AQ 250 mg | - | - | - | - | 1件: 284 284 💬 |
1647 | SSP-004184AQ 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1648 | SSP-004184AQ 375 mg | - | - | - | - | 1件: 284 284 💬 |
1649 | SSP-004184AQ 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1650 | SSP-004184AQ 50 mg | - | - | - | - | 1件: 284 284 💬 |
1651 | SSP-004184AQ 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
1652 | ST-0529 | - | - | - | - | 1件: 97 97 💬 |
1653 | ST10-021 | - | - | - | - | 2件: 96 96, 97 💬 |
1654 | Standard analgesia use [Volatile Anesthesia] | - | - | - | - | 1件: 70 70 💬 |
1655 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
1656 | Standard Vitamin D3 Supplementation | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 60 60 💬 |
1657 | Standard-dose vitamin D (400IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
1658 | Standardized Ginkgo Biloba Extract (EGb 761 (r) | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 18 18 💬 |
1659 | STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1660 | STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1661 | STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 2件: 96 96, 97 💬 |
1662 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
1663 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
1664 | STG-001 | 1件: STG-001 STG-001 | - | - | - | 1件: 301 301 💬 |
1665 | STK-001 | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
1666 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
1667 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
1668 | Stromal Vascular fraction | - | - | - | - | 1件: 51 51 💬 |
1669 | Stromal vascular fraction (SVF) | - | - | - | - | 1件: 96 96 💬 |
1670 | STW5-II (Iberogast N, BAY98-7410) | - | - | - | - | 1件: 97 97 💬 |
1671 | Subjects will undergo the 123-I IBVM imaging visit | - | - | - | - | 1件: 6 6 💬 |
1672 | Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus | - | - | - | - | 1件: 90 90 💬 |
1673 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
1674 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
1675 | Supplementation with vitamin D2/D3 | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
1676 | Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
1677 | Suspension containing 250 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
1678 | Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
1679 | Suspension containing 2500 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
1680 | SUSPENSION CONTAINING 7500 EMBRYONATED VIABLE TRICHURIS SUIS OVA/15ML | - | - | - | - | 1件: 97 97 💬 |
1681 | Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
1682 | Suspension of 7500 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
1683 | Suspension of autologous CD34+cells transduced with the G1XCGD viral vector | - | - | - | - | 1件: 65 65 💬 |
1684 | T cell vaccination | - | - | - | - | 1件: 13 13 💬 |
1685 | T-Cell Vaccination | - | - | - | - | 1件: 13 13 💬 |
1686 | TAK-018 | - | - | - | - | 1件: 96 96 💬 |
1687 | TAK-071 | - | - | - | - | 1件: 6 6 💬 |
1688 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 💬 |
1689 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 💬 |
1690 | TAK-715 | 1件: TAK-715 TAK-715 | - | - | - | 1件: 46 46 💬 |
1691 | TAK-715 and methotrexate | 2件: Methotrexate Methotrexate, TAK-715 | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1692 | TAK-755 | - | - | - | - | 1件: 64 64 💬 |
1693 | TAK-755 or BAX930 or SHP655 | - | - | - | - | 1件: 64 64 💬 |
1694 | TAK-755 orBAX930 or SHP655 | - | - | - | - | 1件: 64 64 💬 |
1695 | TAK-771 | - | - | - | - | 2件: 14 14, 65 💬 |
1696 | TAK-783 | - | - | - | - | 1件: 46 46 💬 |
1697 | TAK-783 and methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1698 | Tavapadon 0.25 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1699 | Tavapadon 0.25mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1700 | TBE-vaccine | - | - | - | - | 1件: 46 46 💬 |
1701 | Teduglutide (ALX-0600) | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1702 | Teduglutide 0.05 | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1703 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1704 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1705 | Teduglutide 0.2 mg | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1706 | TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY] | 2件: Tenofovir Tenofovir, Tenofovir alafenamide | 2件: Tenofovir
Tenofovir
,
Tenofovir alafenamide
💬 | - | - | 1件: 13 13 💬 |
1707 | Terguride 0,5mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
1708 | Terguride 0.5 mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
1709 | Tetanus + pnemococcal vaccines alone | - | - | - | - | 1件: 46 46 💬 |
1710 | Tetanus diphtheria toxoid vaccine (Td) | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
1711 | Tetanus diphtheria toxoids vaccine | - | - | - | - | 1件: 13 13 💬 |
1712 | Tetanus toxoid (TT) containing vaccine (Td, Tdap) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
1713 | Tetanus toxoid adsorbed booster vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 💬 |
1714 | Tetanus Toxoid Adsorbed Vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 💬 |
1715 | Tetanus toxoid vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
1716 | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) | 3件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated), Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), Pertussis vaccine | 1件: Pertussis vaccine
Pertussis vaccine
💬 | - | - | 1件: 46 46 💬 |
1717 | Tetanus vaccin | - | - | - | - | 1件: 11 11 💬 |
1718 | Tetanus, diphtheria, and acellular pertussis vaccine | 1件: Pertussis vaccine Pertussis vaccine | 1件: Pertussis vaccine
Pertussis vaccine
💬 | - | - | 1件: 13 13 💬 |
1719 | TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML | - | - | - | - | 1件: 222 222 💬 |
1720 | Tezepelumab via APFS | 1件: Tezepelumab Tezepelumab | 1件: Tezepelumab
Tezepelumab
💬 | 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 💬 |
1721 | TgAAC94 gene therapy vector | - | - | - | - | 2件: 46 46, 271 💬 |
1722 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
1723 | The effectiveness of Xeljanz in rheumatoid arthritis patients | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1724 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
1725 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
1726 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
1727 | TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED) | - | - | - | - | 1件: 46 46 💬 |
1728 | Timolol Alcon 0.5% collyre | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
1729 | TLL-018 | - | - | - | - | 1件: 46 46 💬 |
1730 | TMI-005 | - | - | - | - | 1件: 46 46 💬 |
1731 | TMI-005 (WAY-177005) | - | - | - | - | 1件: 46 46 💬 |
1732 | TMI-005 WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
1733 | TNR-001 | - | - | - | - | 2件: 46 46, 271 💬 |
1734 | TNR-001, TNFR:FC | - | - | - | - | 1件: 271 271 💬 |
1735 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
1736 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
1737 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1738 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1739 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1740 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1741 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1742 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
1743 | Tocopherol (vit E) | 1件: Tocopherol Tocopherol | 1件: Tocopherol
Tocopherol
💬 | - | - | 1件: 257 257 💬 |
1744 | Tofacitinib (Xeljanz) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1745 | Tofacitinib (Xeljanz®) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1746 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1747 | Tofacitinib 10 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
1748 | Tofacitinib 5 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 50 💬 |
1749 | Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
1750 | Tofacitinib XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 271 💬 |
1751 | Tolvaptan 7.5 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1752 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
1753 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
1754 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
1755 | Topical Pentoxifylline Gel (Vehicle +PTX) | 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline
Pentoxifylline
💬 | - | - | 1件: 56 56 💬 |
1756 | Topical Vehicle | - | - | - | - | 1件: 278 278 💬 |
1757 | Tovaxin Autologous T Cell Vaccine | - | - | - | - | 1件: 13 13 💬 |
1758 | Trade Name Xarelto | 1件: Rivaroxaban Rivaroxaban | 1件: Rivaroxaban
Rivaroxaban
💬 | 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 1件: 49 49 💬 |
1759 | Trametinib (0.5 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
1760 | TransCon CNP 3.9 mg CNP-38/vial | - | - | - | - | 1件: 276 276 💬 |
1761 | TransCon hGH (ACP-011) | - | - | - | - | 1件: 78 78 💬 |
1762 | TransCon hGH (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
1763 | TransCon hGH (ACP-011) - 12.1mg | - | - | - | - | 1件: 78 78 💬 |
1764 | TransCon hGH (ACP-011) - 24.2mg | - | - | - | - | 1件: 78 78 💬 |
1765 | TransCon hGH CT-301 (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
1766 | Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL17A1-encoding retroviral vector | - | - | - | - | 1件: 36 36 💬 |
1767 | Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL7A1-encoding retroviral vector | - | - | - | - | 1件: 36 36 💬 |
1768 | Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL7A1-encoding retroviral vector, obtained from secondary culture of ex vivo expanded autologous human keratinocytes. | - | - | - | - | 1件: 36 36 💬 |
1769 | Treatment vs control bread | - | - | - | - | 1件: 97 97 💬 |
1770 | Trichuris suis ova (eggs), embryonated, viable | - | - | - | - | 1件: 13 13 💬 |
1771 | Trivalent chromium versus synthetic and/ or biological DMARDs | 1件: Chromium Chromium | - | - | - | 1件: 46 46 💬 |
1772 | Trivalent inactivated influenza vaccine | - | - | - | - | 1件: 46 46 💬 |
1773 | Trivalent seasonal influenza vaccine | - | - | - | - | 1件: 13 13 💬 |
1774 | TRU-015 | 1件: TRU-015 TRU-015 | - | - | - | 3件: 46 46, 49, 222 💬 |
1775 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
1776 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
1777 | TSO 7500 | - | - | - | - | 1件: 96 96 💬 |
1778 | TT Vaccine | - | - | - | - | 1件: 13 13 💬 |
1779 | TV-7110 | - | - | - | - | 1件: 2 2 💬 |
1780 | TV-7820 | - | - | - | - | 1件: 8 8 💬 |
1781 | TVP-1012 0.5mg | - | - | - | - | 1件: 6 6 💬 |
1782 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
1783 | TY-0305 | - | - | - | - | 1件: 58 58 💬 |
1784 | UF-021 | - | - | - | - | 1件: 90 90 💬 |
1785 | UF-021 (isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
1786 | UF-021(isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
1787 | UK 092480 | - | - | - | - | 1件: 86 86 💬 |
1788 | ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
1789 | UN-ALPHA-R 0.25µg | - | - | - | - | 1件: 235 235 💬 |
1790 | Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1791 | UT-15C 0.25 mg | - | - | - | - | 1件: 86 86 💬 |
1792 | UVADEX and UVAR XTS Photopheresis System | 1件: Methoxsalen Methoxsalen | 1件: Methoxsalen
Methoxsalen
💬 | - | - | 1件: 96 96 💬 |
1793 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 💬 |
1794 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 💬 |
1795 | UX701 (1.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
1796 | UX701 (2.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
1797 | UX701 (5.0 × 10^12 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
1798 | Vaccination with vaccine against hepatitis A and B | - | - | - | - | 1件: 299 299 💬 |
1799 | Vaccine Vivotif + Vaccine Dukoral | 6件: Recombinant Cholera Toxin B Subunit Recombinant Cholera Toxin B Subunit, Typhoid Vaccine Live, Vibrio cholerae Inaba 48 classical biotype, heat inactivated, Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, heat inactivated | - | - | - | 1件: 97 97 💬 |
1800 | Vaccine Vivotif + Vaccine Dukoral + oats | 7件: Oat Oat, Recombinant Cholera Toxin B Subunit, Typhoid Vaccine Live, Vibrio cholerae Inaba 48 classical biotype, heat inactivated, Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, heat inactivated | - | - | - | 1件: 97 97 💬 |
1801 | Valganciclovir (VGC) | 1件: Valganciclovir Valganciclovir | 1件: Valganciclovir
Valganciclovir
💬 | - | - | 1件: 331 331 💬 |
1802 | Valganciclovir [Valcyte] | 1件: Valganciclovir Valganciclovir | 1件: Valganciclovir
Valganciclovir
💬 | - | - | 1件: 299 299 💬 |
1803 | Valproic Acid (VPA) | 1件: Valproic acid Valproic acid | 1件: Valproic acid
Valproic acid
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 💬 |
1804 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1805 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1806 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1807 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1808 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1809 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1810 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1811 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1812 | Varicella Zoster Vaccine | - | - | - | - | 1件: 46 46 💬 |
1813 | Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 299 299 💬 |
1814 | Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana | - | - | - | - | 1件: 19 19 💬 |
1815 | Vedolizumab Intravenous (IV), Vedolizumab Subcutaneous (SC), Placebo IV | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1816 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 💬 |
1817 | Veltuzumab solution 75mg/ml | 1件: Veltuzumab Veltuzumab | 1件: Veltuzumab
Veltuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1818 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 💬 |
1819 | Verum arm receiving Vitamin D oil | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
1820 | Vigabatrin: Vigabatrin new ST formulation then Sabril® | 1件: Vigabatrin Vigabatrin | 1件: Vigabatrin
Vigabatrin
💬 | 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 💬 |
1821 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 💬 |
1822 | Vinblastine, vincristine, prednisone, daunorubicin | 4件: Daunorubicin Daunorubicin, Prednisone, Vinblastine, Vincristine | 4件: Prednisone
Prednisone
,
Daunorubicin
,
Vinblastine
,
Vincristine
💬 | 12件: NR3C1 NR3C1, TOP2A, TOP2B, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬 | 1件: 65 65 💬 |
1823 | Vit C Vit E Zn Se | - | - | - | - | 1件: 113 113 💬 |
1824 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
1825 | Von Willebrand factor and coagulation factor VIII in combination | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
1826 | VPD-737 | - | - | - | - | 1件: 36 36 💬 |
1827 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1828 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 💬 |
1829 | VT-001 | - | - | - | - | 1件: 66 66 💬 |
1830 | VWD factor VIII concentrate | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1831 | VX-661 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
1832 | VX-661, VRT-893661 | - | - | - | - | 1件: 299 299 💬 |
1833 | VX-661/ivacaftor (VX-770) 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1834 | VX-661/ivacaftor 50 mg/ 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1835 | VX-661/VX-770 | - | - | - | - | 1件: 299 299 💬 |
1836 | VX-661/VX-770 (TEZ/IVA) | - | - | - | - | 1件: 299 299 💬 |
1837 | VX-702 | 1件: VX-702 VX-702 | - | - | - | 1件: 46 46 💬 |
1838 | VX-745 | - | - | - | - | 1件: 8 8 💬 |
1839 | VX-77 | - | - | - | - | 1件: 299 299 💬 |
1840 | VX-770 | - | - | - | - | 1件: 299 299 💬 |
1841 | VX-770, VRT-8130077 | - | - | - | - | 1件: 299 299 💬 |
1842 | VX-770, VRT-813077 | - | - | - | - | 1件: 299 299 💬 |
1843 | VX-809 & VX-770 | - | - | - | - | 1件: 299 299 💬 |
1844 | VX-809 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
1845 | VX-809, VRT-826809 | - | - | - | - | 1件: 299 299 💬 |
1846 | VX-809/VX-770 | - | - | - | - | 1件: 299 299 💬 |
1847 | VYNT-0126 | - | - | - | - | 1件: 156 156 💬 |
1848 | Warfarin+ Vitamin K | 2件: Phylloquinone Phylloquinone, Warfarin | 1件: Warfarin
Warfarin
💬 | 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 46 46 💬 |
1849 | White chocolate (0% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
1850 | With U-VANCO (vancomycin hydrochloride) | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 1件: 70 70 💬 |
1851 | Without U-VANCO (vancomycin hydrochloride) | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 1件: 70 70 💬 |
1852 | WVE-003 | - | - | - | - | 1件: 8 8 💬 |
1853 | WVE-004 | - | - | - | - | 2件: 2 2, 127 💬 |
1854 | X vivo gene therapy | - | - | - | - | 1件: 65 65 💬 |
1855 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
1856 | Xeljanz XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1857 | XGEVA - 120 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 1.7 ML 4 FLACONCINI | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
1858 | XmAb5871_1.0MG | - | - | - | - | 1件: 46 46 💬 |
1859 | XmAb5871_10.0MG | - | - | - | - | 1件: 46 46 💬 |
1860 | XmAb5871_3.0MG | - | - | - | - | 1件: 46 46 💬 |
1861 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 💬 |
1862 | Yellow fever vaccine | 1件: Yellow fever vaccine Yellow fever vaccine | 1件: Yellow fever vaccine
Yellow fever vaccine
💬 | - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 💬 |
1863 | Yellow Fever vaccine (17D) | 1件: Yellow fever vaccine Yellow fever vaccine | 1件: Yellow fever vaccine
Yellow fever vaccine
💬 | - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 💬 |
1864 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
1865 | Yondelis 0.25 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
1866 | Zolgensma 2 x 1013 vector genomes/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
1867 | Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
1868 | Zostavax (varicella zoster virus) vaccine | 1件: Varicella zoster vaccine (live/attenuated) Varicella zoster vaccine (live/attenuated) | - | - | - | 1件: 46 46 💬 |
1869 | Zostavax vaccine | 1件: Varicella zoster vaccine (live/attenuated) Varicella zoster vaccine (live/attenuated) | - | - | - | 2件: 46 46, 49 💬 |
1870 | ZSP1603 7.5 mg | - | - | - | - | 1件: 85 85 💬 |
1871 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
1872 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
1873 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
1874 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |